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Abdominal obesity is a part of insulin resistance syndrome that is closely
linked to increased risk of coronary artery disease (CAD). Because fat tissue acts as
an endocrine target and source of hormone production, increased metabolism or
production of chemical messengers in fat tissue may result in metabolic perturbations
that contribute to occurrence and recurrence of coronary events. This dissertation
research entails two separate approaches. The first study, a cross-sectional analysis,
sought to determine whether serum cortisol responses to oral glucose loading are
associated with abdominal obesity, non-esterified fatty acid (NEFA) suppression, and
self-reported symptoms of depression in 26 non-diabetic coronary patients. We
conclude that lower cortisol responses to oral glucose loading are associated with
abdominal obesity, reduced NEFA suppression, and fewer symptoms of depression
(P0.028). Future prospective studies should determine whether psychosocial risk
factors, such as depression and anxiety, increase cortisol production, whether increases
in cortisol production act synergistically with a positive energy balance in the
Redacted for Privacydevelopment of abdominal obesity, and whether increases in abdominal obesity lead to
increases in cortisol metabolism and insulin resistance.
C-reactive protein (CRP) is a marker of low-grade inflammation that is
associated with increased risk for recurrent events in coronary patients. Fat tissue also
secretes proinflammatory cytokines that stimulate hepatic production of CRP. Thus,
the second study, an intervention study, sought to determine whether the first three
months of cardiac rehabilitation could reduce serum concentrations of CRP and the
proinflammatory cytokine, tumor necrosis factor-a (TNF-a), in our non-diabetic
coronary patients (N=26). Results from the intervention study showed significant
reductions in serum CRP levels (P=O.012) that were associated with reductions in
waist circumferences after cardiac rehabilitation (r=O.3 9, P=O.049). However,
changes in serum TNF-a levels after cardiac rehabilitation were nonsignificant
(P=O.869). Thus, we conclude that cardiac rehabilitation may reduce the severity of
low-grade inflammatory conditions, in part, through reductions in waist circumference
in non-diabetic coronary patients.©Copyright by Kayoko Ogimoto
September 27, 2000
All rights ReservedCortisol, Abdominal Obesity, and Reductions in Inflammation after Cardiac
Rehabilitation in Non-Diabetic Coronary Patients
by
Kayoko Ogimoto
A DISSERTATION
submitted to
Oregon State University
in partial fulfillment of
the requirements for the
degree of
Doctor of Philosophy
Presented September 27, 2000
Commencement June 2001Doctor of Philosophy dissertation of Kayoko Ogimoto presented on September 27,
2000
APPROVED:
Professor. renresentin Human
of Gràdute School
I understand that my dissertation will become part of the permanent collection of
Oregon State University libraries. My signature below authorizes release of my
dissertation to any reader upon request.
gimoto,
Redacted for Privacy
Redacted for Privacy
Redacted for Privacy
Redacted for PrivacyACKNOWLEDGEMENT
This dissertation was supported by a grant from the John C. Erkkila, M.D.
Endowment for Health and Human Performance, Good Samaritan Hospital
Foundation, Corvallis, OR. I'd also like to acknowledge those individuals who
contributed their time and effort to my study: Kern Eason, R.N. and Diane Arney,
R.N, the staff members at the Good Samaritan Hospital, 26 study participants, and our
research assistant, Jessica Jacks, who is also a close friend of mine.
Special thanks to my graduate committee members, Dr. Jean Hall, Dr. Ilene
Kleinsorge, Dr. Marjorie Reed, Dr. Christine Snow, Dr. Maret Traber, and Dr.
Rosemary Wander, for their encouragement, guidance, and support that each provided
throughout my graduate work at OSU. I truly admire your dedication as a researcher
and your success in the field. You are my inspiration.
I'd also like to thank to the Department Chair, Dr. Anthony Wilcox, for his
thoughtfulness and genuine concerns toward students. Tony, I felt like I can talk to
you about any problems I had. Thank you for always being such good listening ears.
Looking back the past four years of my life in Corvallis, I realize how many
people have helped me to accomplish my academic goals. I want to share this degree
with those individuals who hold special place in my heart. First, my dearest friend,
Andy Dale. Who would have thought that we ended up being such close friends?
Thank you for being there for me when I most needed your support. Thank you for
putting up with my unpredictable storm of temper. You truly are a GOOD man. I
have never heard you say bad things about others. You are the most trusting person I
have ever met.Gay Timken, my best buddy in Corvallis. We had a blast, didn't we? Eating
sushi every week after our "soothing" yoga session, going on a long run in the forest,
and of course, there was this drinking. You really touched my heart when you said to
me, "You are my family". I admire your ambition and determination to succeed in
your discipline, and your openness and warm personality. Hey, BIG AMERICAN
GIRL, we'll be in touch!
Kaoru Yamaguchi. You are one of very few Japanese I know who would not
think or say to me, "What are you trying to prove, crazy? Just get married and have
kids, already". We've known each other for almost 20 years. Whenever I think about
our friendship, it reminds me of a song, "Wind beneath my wings". Kind of corny,
but it's true. Although we are very different in so many ways, I admire your
intelligence and talent. You will always be my hero.
Members in my faculty staff aerobics class. Rich, Sandy, Janice, Barb, Joan,
Gerald, Georgine, Nancy, Sally, and many, many more.... Thank you for being so
sweet to me. Your smile helped me overcome the obstacles I had from time to time. I
truly enjoyed exercising with you. I hope I did something good to contribute to your
health. Stay fit!
Lynne David, Jessica Jacks, and Jenny Slawta, you are true friends of mine.
My Japanese friends in Corvallis, Hiro-san, Makiko san, Raina-chan, Yoko-chan,
Motoko-chan, Asako-san, Emi-chan, Yoshiko-san, Yuka-chan, Tomoko-san, Yoshie-
san, and Daiki-kun, etc... Thank you for your friendship and support. You reminded
me that seniority means something in our culture. And thanks to the fellow graduate
students in the Department of EXSS, especially those who took me out to celebrate thecompletion of my defense, Deborah John, Kathy Gunter, Susan Levy, and Robyn
Fuchs.
Finally and most importantly, my deepest and special thanks to my mentor, Dr.
Dan P. Williams. You are the only person who truly knows what it means to me to
complete this degree. I am certain that you share the sense of accomplishment and
overwhelming emotions right at this moment with me. I do not know how to express
my gratitude for the time and effort you put into my dissertation project. I can be
really stubborn and demanding, and am not the easiest student to deal with. But you
showed tremendous patience,nintai,with me, and never doubt my ability to succeed
in accomplishing my academic goals at OSU. You have taught me how to think
critically, write scientific papers, run biochemical assays, and run statistical analyses
in arightway (also in ahardway). What I was not able to learn from you was
English grammar, however ©. Thank you for giving me a confidence to become a
scientist. You and I have also created a special bonding beyond a mentor-student
relationship over years. We have shared a loss of a loved one, and pain and sorrow we
needed to overcome. Through our personal experience, we became able to appreciate
our lives as a constantly changing,moment to moment.I thank you for sharing the
deepest thoughts with me and teaching me important life lessons. You will always be
a special person to me. Thank you, for being who you are. Thank you, for coming
into my life.I
TABLE OF CONTENTS
pg
CHAPTER 1: INTRODUCTION. 1
Public Health Impact of Coronary Artery Disease.......................................1
The Need for Effective Cardiac Rehabilitation Programs...............................2
Link Between Insulin Resistance and CAD................................................3
Insulin Resistance in Fat Tissue............................................................. 5
Interactions among Psychosocial Stress, Cortisol, and Abdominal
Obesity-Related Insulin Resistance.......................................................... 7
Inflammation and CAD...................................................................... 9
Role of Fat Tissue as a Source of Cytokines.............................................10
Reductions in Inflammation after Cardiac Rehabilitation.............................11
Statement of Purpose......................................................................... 12
CHAPTER 2: CORTISOL RESPONSES TO ORAL GLUCOSE ARE
ASSOCIATED WITH ABDOMiNAL OBESITY, NON-ESTERIFIED FATTY
ACID SUPPRESSION, AND DEPRESSION IN NON-DIABETIC CORONARY
PATIENTS...................................................................................... 15
Abstract....................................................................................... 16
Introduction................................................................................... 17
Materialsand Methods......................................................................18
Results......................................................................................... 22
Discussion.................................................................................... 28
References.................................................................................... 32TABLE OF CONTENTS (Continued)
CHAPTER 3: REDUCTIONS IN SERUM C-REACTIVE PROTEIN AFTER
CARDIAC REHABILITATION IN NON-DIABETIC CORONARY PATIENTS... 35
Abstract........................................................................................ 36
Introduction................................................................................... 37
Materials and Methods.......................................................................38
Results......................................................................................... 43
Discussion..................................................................................... 47
References..................................................................................... 52
CHAPTER 4: CONCLUSION................................................................57
BIBLIOGRAPHY..............................................................................61
APPENDICES ................................................................................... 71
Appendix A: Institutional Review Board Approval......................................72
Appendix B: Informed Consent.............................................................75
Appendix C: Screening Form...............................................................81
Appendix D: Blood Draw Assessment Form..............................................83
Appendix E: Body Composition Data Collection Sheet.................................87
Appendix F: Attendance Record............................................................88
Appendix G: 7-Day Physical Activity Recall Questionnaire...........................89
Appendix H: Food Questionnaire...........................................................95
Appendix I: The Center for Epidemiologic Studies Questionnaire..................103
Appendix J: Medical History Questionnaire..............................................107LIST OF FIGURES
Figure Page
2.1.Metabolic and hormonal responses to oral glucose loading.....................25
2.2Association between mean serum cortisol response to oral glucose loading
and cortisol predicted from abdominal obesity and depression scores.........26
2.3.Association between mean serum cortisol response to oral glucose loading
and cortisol predicted from mean serum NEFA responses and depression
scores.................................................................................... 27
3.1Fasting serum C-reactive protein levels before and after three months of
cardiac rehabilitation.................................................................. 44
3.2Fasting serum tumor necrosis factor-ct levels before and after three months
of cardiac rehabilitation in non-diabetic coronary patients......................45LIST OF TABLES
Table Page
2.1.Descriptive characteristics of non-diabetic coronary patients...................23
3.1Changes in body composition after cardiac rehabilitation in non-diabetic
coronary patients ...................................................................... 46
3.2Intercorrelation matrix of changes in circulatory markers of inflammation
and body composition after cardiac rehabilitation in non-diabetic coronary
patients................................................................................. 47DEDICATION
To the loving memory of my mother,Katsuko Oikawa,
Rinju no toko de chikatta
Kanarazu hakase-gou o totte kinasai to
Anata no sono kotoba dakega
Watashi no hagemi deshita.
Arigatou, Okasan...CORTISOL, ABDOMINAL OBESITY, AND REDUCTIONS IN
INFLAMMATION AFTER CARDIAC REHABILITATION IN
NON-DIABETIC CORONARY PATIENTS
CHAPTER 1
INTRODUCTION
Public Health Impact of Coronary Artery Disease
Coronary artery disease (CAD) is the single largest killer of Americans.
Although thedeathrate from CAD has declined by 25% over the past decade,
increased coronary event survival, due in part, to the advancement of medical
technology, may contribute to the substantial number of coronary event recurrences in
individuals who experienced a previous heart attack (AHA, 1999). In addition, CAD
is also the leading cause of premature, permanent disability in the U.S. labor force,
accounting for 19% of disability allowances by the Social Security Administration
(AHA, 1999).
The economic burden of CAD is staggering, with the total cost of CAD
estimated to be nearly $120 billion in the U.S. in the year 2000 alone (AHA, 1999). In
particular, the number of expensive CAD procedures has increased by 350% over the
past two decades, which largely contributes to the increasing costs of CAD (AHA,
1999). In 1995, the average cost of surgical procedures for CAD were $10,000 per
cardiac catheterization, $45,000 per coronary artery bypass graft (CABG), and
$20,000 per percutaneous transluminal coronary angioplasty (PTCA) (AHA, 1999).
Unfortunately, these expensive surgical procedures alone do not effectively prevent2
the occurrence or recurrence of coronary events and hospitalization, and often require
subsequent re-vascularization procedures (Ellis et al., 1991). Thus, the quality and
delivery of secondary prevention programs must be improved to further reduce the
risk of coronary events, to reduce the need for costly procedures, and to improve the
quality of life in all patients living with CAD.
The Need for Effective Cardiac Rehabilitation Programs
Cardiac rehabilitation programs are comprehensive, long-term programs
involving medical evaluation and cardiac risk factor modification through prescribed
exercise, nutritional counseling, pharmacological management, smoking cessation,
psychosocial stress management, and vocational counseling (Wenger et al., 1995).
Compelling scientific evidence demonstrates that such interventions extend overall
survival, improve quality of life, decrease the need for costly and invasive medical
procedures, reduce the incidence of myocardial infarction (MI), and reduce the
economic burden of CAD (AHA, 1995). For instance, Ornish et al. found that 5 years
of intensive lifestyle modification in CAD patients resulted in the regression of
coronary atherosclerosis and the reduction in cardiac events (Ornish et al., 1998).
Similarly, Haskel et al. demonstrated that 4 years of multiple risk factor reduction
program resulted in reductions in the rates of atherosclerotic progression and re-
hospitalization (Haskell et al., 1994).
Although health benefits of cardiac rehabilitation are overwhelming, physician
referrals and patient enrollments remain low. For instance, recent estimates report thatonly 15% of qualified patients who have undergone a MI or a CABG actually enroll in
phase II (early outpatient) cardiac rehabilitation programs (AHA, 1994). To increase
enrollments in cardiac rehabilitation programs, patients, physicians, health care
specialists, and health insurance payers should be educated about the health benefits of
cardiac rehabilitation programs. Accordingly, a team approach among healthcare
professionals needs to be taken to design more effective intervention programs that
can maximize health benefits, improve cost-effectiveness, increase patient compliance,
and enhance the availability and delivery of preventive health care services for the
large population of individuals with CAD.
Link between Insulin Resistance and CAD
Atherosclerosis is a narrowing of arteries in which the inner layers of the
arterial walls become thick and irregular due to endothelial injury and the eventual
accumulation of plaques. It is thought that endothelial injuries initiate the atherogenic
process (Ross 1993), which triggers an inflammatory response, resulting in the
migration and proliferation of vascular smooth muscle cells and the accumulation of
oxidized LDL in the arterial walls (atherosclerotic progression) (Quinn et al., 1987).
When an unstable atherosclerotic plaque in a coronary artery ruptures, it stimulates
thrombosis or clot formation, leading to an occlusion of blood flow, myocardial
ischemia, myocardial hypoxia, and possibly even myocardial necrosis.
Insulin resistance refers to the inability of normal insulin levels to achieve an
appropriate biological response (Kahn, 1978). Insulin resistance and its associatedmetabolic and hemodynamic disorders are closely linked to an increased risk of CAD
(Korpilahti et al., 1998). Such disorders, collectively called Syndrome X, include
hyperinsulinemia, elevated plasma triglyceride levels, lower high-density lipoprotein
cholesterol (HDL-C) levels, hypertension, higher plasminogen activator inhibitor-i
(PAT-i) levels (Reaven, 1995), and abdominal obesity (Després, 1997). Substantial
evidence demonstrated that the state of insulin resistance plays an important role in the
etiology of both the chronic precursor (atherosclerotic plaque formation, progression
and instability) (Bressler et al., 1996; Bressler & DeFronzo, 1994; Korpilahti et al.,
1998; Osanai et al., 1998; Plutzky, 1999; Suzuki et al., 1996; Yudkin et al., 1999) and
the acute "trigger" (plaque rupture and undissolved fibrin clot formation) to heart
attacks (Festa et al., 1999; Sobel 1999).
While most studies have focused on atherosclerotic risk factor modification as
the measure of effective cardiac rehabilitation programs (Haskell et al., 1994; Ornish
et al., 1998), a greater stability of atherosclerotic plaques is an equally important goal
for reducing the occurrence of future coronary events (Piutzky, 1999). To design
effective cardiac rehabilitation programs, it is imperative to understand the
pathophysiological mechanisms for disease progression and event precipitation. Thus,
our approach is to focus on the management of the underlying neuroendocrine
disorder, insulin resistance, rather than treating the myriad of metabolic risk factor
consequences of insulin resistance. Taking this holistic approach, we hope to improve
the effectiveness of cardiac rehabilitation programs by correcting the underlying
causes of CAD events.Insulin Resistance in Fat Tissue
Deterioration of insulin action in individuals with insulin resistance is
characterized by an impairment of glucose uptake by muscle and adipose tissues as
well as an overproduction of glucose by the liver (Ivy et al., 1999). Skeletal muscle
tissue has been a target of research as the primary site of insulin resistance because it
is the largest organ in the body for glucose disposal. However, the earlier research
focusing on skeletal muscle is overly narrow because this view ignores the profound
effects of insulin on fat metabolism.
The characteristics of insulin resistance in fat tissue include inhibition of
lipogenesis and stimulation of lipolysis (Couillard et al., 1998). The consequence of
low rate of lipogenesis could be postprandia! (after meal) hypertriglyceridemia in the
form of elevated chylomicrons, whereas the consequence of elevated lipolysis could
be inadequate suppression of postprandial non-esterified fatty acids (NEFA), which in
turn, provide metabolic substrate for very low density lipoprotein (VLDL) synthesis in
the liver (Frost et al., 1998). Postprandial hypertriglyceridemia together with an
impaired postprandia! NEFA suppression would ultimately result in an increased
triglyceride delivery to the lipid core of atherosclerotic plaques (Gronholdt et al.,
1998). The softer, less-dense, and more triglyceride-rich plaques are less stable and
more susceptible to rupture (Gronholdt et al., 1998). Therefore, the exacerbation of
fasting and postprandia! lipidemia associated with insulin resistance in fat tissue is
likely to contribute to plaque instability and an increased likelihood for rupture.
Recent studies show that the vulnerability of atherosclerotic plaque to rupture, ratherthan the degree of stenosis, is the primary determinant of acute coronary events
(Plutzky, 1999). Thus, chronic elevations in serum triglyceride and NEFA due to fat
tissue insulin resistance may play an important role in the etiology of CAD events.
Besides contributing to atherosclerotic plaque instability, insulin resistance in
fat tissue may also exacerbate the local and for systemic insulin resistant state, creating
a vicious cycle. A greater release of NEFA from fat tissue into circulation causes an
impairment of insulin-stimulated glucose uptake in skeletal muscle, an enhanced fatty
acid oxidation in skeletal muscle, a greater gluconeogenesis in the liver, a reduced
extraction of insulin by the liver, and a greater secretion of insulin by the pancreas
(Ivy et al., 1999). Thus, persistently elevated circulating NEFA levels result in
hyperglycemia and hyperinsulinemia, which are common metabolic disturbances in
the insulin resistant state.
Abdominal obesity is closely associated with insulin resistance and is a major
risk factor for non-insulin dependent diabetes mellitus (NIDDM) and CAD (Després,
1997). The association between abdominal obesity and insulin resistance may be
explained, in part, by the evidence that visceral abdominal fat tissue, in comparison
with subcutaneous fat tissue, exhibits higher catecholamine-induced lipolytic activity
and is less sensitive to the anti-lipolytic action of insulin, resulting in a greater release
of NEFA (Ostman et al., 1979). Elevations in circulating NEFA are associated with
the development of diabetes, independent of insulin secretory defects and insulin
resistance (Charles et al., 1997), which suggests that elevated NEFA play an important
role in the development of diabetes. Therefore, serum NEFA levels, rather thantraditionally measured serum glucose levels, may be a more relevant physiological
marker of insulin resistance in coronary patients.
Taken together, management of elevated serum NEFA through reductions in
insulin resistance and abdominal obesity may stabilize vulnerable atherosclerotic
plaques, thereby reducing the likelihood of plaque rupture and future coronary events.
Interactions among Psychosocial Stress, Cortisol, and Abdominal Obesity-Related
Insulin Resistance
Insulin resistance alone in fat tissue would lead to reductions in fat uptake and
storage as well as to increases in fat breakdown and release. However, individuals
with insulin resistance are frequently obese, especially in the abdominal region
(Pouliot et al., 1992). We speculated that the antagonistic and potentiating
relationships between insulin and cortisol might help to explain the paradoxical co-
existence of obesity and insulin resistance in fat tissue.
Cortisol is a stress hormone, which is produced in the adrenal cortex under the
control of the hypothalamic-pituitary-adrenal (HPA) axis. Cortisol opposes insulin
action in fat tissue by antagonizing the insulin-mediated stimulation of glucose uptake
and the insulin-mediated inhibition of lipolysis (Cigolini & Smith, 1979). Together,
the antagonistic effects of cortisol on insulin action in fat tissue may contribute to
increases in circulating glucose and NEFA levels (Brindley, 1995). By contrast to
these antagonistic effects, cortisol also potentiates insulin action by promoting fat
storage, particularly in visceral fat (Cigolini & Smith, 1979). Together, insulin andcortisol promote fat storage through their cooperative stimulatory effects on
lipoprotein lipase activity in fat tissue.
Psychosocial stress, such as chronic depression, may result in hyperactivity of
the HPA axis, which, in turn, results in the overproduction of cortisol (Peeke &
Chrousos, 1995). Psychosocial stress has been shown to be associated with obesity-
or abdominal obesity-related insulin resistance (Räikkönen et al., 1996, Rosmond et
al., 1998) and CAD (Williams, 1987). Thus, accumulation of abdominal fat in the
insulin resistant state may be attributed, in part, to overproduction of cortisol resulting
from chronic depression.
An increase in circulating insulin and a decrease in circulating cortiso! after
oral glucose loading reflect normal endocrine function (Keltikangas-Jarvinen et al.,
1998). However, individuals with insulin resistance, general obesity, and abdominal
obesity display an exaggerated morning cortisol suppression (Fernández-Real, 1997;
Hautanen & Adlercreutz, 1993; Keltikangas-Jarvinen et al., 1998). Moreover,
individuals with obesity or abdominal obesity display elevated levels of urinary
cortisol excretion, yet basal circulating cortisol levels are normal or even low (Mann
et al., 1992; Stewart etal., 1999). The co-existence of elevated urinary cortisol
excretion with either normal or low circulating cortisol, as we!! as an exaggerated
morning cortisol suppression, suggests that individuals with abdominal obesity may
have an increased metabolic clearance of cortisol. In support, a higher density of
glucocorticoid receptors has been reported in visceral adipocytes as compared to
adipocytes in other regions of the body (Rebuffé-Scrive et al., 1985). Thus, an
enhanced metabolic clearance of cortisol due to the over-abundance of glucocorticoid9
receptors in abdominal visceral adipocytes may provide an additional local stimulus
for gains in abdominal fat mass by potentiating insulin-stimulated increases in
lipoprotein lipase (LPL) activity immediately following a meal (Bujaiska et al., 1997).
Furthermore, an enhanced metabolic turnover of cortisol in abdominal adipocytes may
partly explain the complex associations among psychosocial stress, insulin resistance,
and abdominal obesity.
Inflammation and CAD
Inflammation is an integral part of the processes of atherothrombosis (Ross,
1999). Atherosclerosis is initiated by endothelial injury, which leads to a series of
inflammatory responses including a release of monocyte-derived cytokines, such as
tumor necrosis factor-a (TNF-a), interleukin-1 (IL-i) and interleukin 6 (IL-6) and
other proinflammatory substances, which promote systemic inflammation and the
synthesis of such hepatic acute phase proteins as C-reactive protein (CRP) (Pickup et
al., 1997). Local inflammation in the vascular endothelium has been implicated in the
erosion of the fibrous cap of advanced atherosclerotic plaques, which contributes to
plaque instability and plaque rupture (Ross, 1999).
CRP is a circulating acute phase protein, which may increase several hundred
fold (Tietz, 1990) in response to tissue injury, infection, or inflammation (Thompson
et al., 1992). However, relatively modest 2 to 3-fold elevations in serum CRP that are
well below the acute-phase inflammatory threshold increase the risk for future
coronary events in patients with a prior myocardial infarction (Tommasi et al., 1999),10
in patients with stable (Haverkate et al., 1997) and unstable angina (Haverkate et al.,
1997; Liuzzo et al., 1994; Thompson et al., 1995) and in patients who have undergone
coronary artery bypass graft surgery (Milazzo et al., 1999). Thus, it is likely that a
more chronic state of low-grade inflammation increases the risk for recurrent coronary
events. Furthermore, the predictive value of modest elevations in CRP are
independent of other coronary risk factors including dyslipidemia (Ridker et al.,
1998a; Ridker et al., 1998b) and subclinical CAD (Tracy et al., 1997).
Role of Fat Tissue as a Source of Cytokines
Fat tissue is traditionally considered as a relatively inert site of fat storage.
Recently, more attention is directed towards its role as an endocrine, autocrine, and
paracrine organ (Sethi & Hotamisligil, 1999). For instance, fat tissue is a source of
proinflammatory cytokines such as TNF-a (Mohamed-Ali, 1997), IL-i, and IL-6
(Baumann & Gauldie, 1994). IL-6 is a major inducer of hepatic production of CRP
(Baumann & Gauldie, 1994), and IL-i and TNF-a, in turn, stimulate the production of
IL-6 (Heinrich et al., 1990). Moreover, in isolated fat cells, IL-6 expression in visceral
fat is greater in visceral than in subcutaneous fat cells (Fried et al., 1998). Thus, we
hypothesized that elevated levels of proinflammatory cytokines, such as IL-6 and
TNF-a, that are secreted from an excessive amount of fat tissue in obesity, may
directly reflect low-grade inflammatory conditions. Alternatively, elevated
proinflammatory cytokines may indirectly reflect low-grade inflammatory conditions
through overproduction of CRP in coronary patients. Thus, the physiological11
consequences of elevated circulating proinflammatory cytokines and acute phase
protein levels in the circulation may provide a novel mechanistic link between
abdominal obesity and CAD.
TNF-ct may not always be released into circulation and thus we do not know
the extent to which the amount of "overspill" from fat tissue into circulation is
contributing to the systemic TNF-a levels. Nevertheless, circulating levels of both
CRP (Haverkate et al., 1997, Koenig et al., 1999; Hak et al., 1999; Visser et al., 1999;
Festa et al., 2000) and TNF-a (Kern et al., 1995; Yudkin et al., 1999) are elevated in
obesity. Moreover, serum TNF-ct is also elevated in CAD patients (Jovinge et al.,
1998; Yudkin et al., 1999), and elevated serum TNF-a is, like CRP, an independent
risk factor for recurrent coronary events in coronary patients (Ridker et al., 2000).
Thus, reductions in fat may result in reductions in serum circulating proinflammatory
cytokines and CRP.
Reductions in Inflammation after Cardiac Rehabilitation
Besides its endocrine role, another possible mechanism by which the
intervention may reduce serum TNF-a is that the TNF-u secreted from
monocytes/macrophages, endothelial cells (Imaizumi et al., 2000), and atherosclerotic
plaques (Barath et al., 1990) may be reduced with cardiac rehabilitation as a result of
the potential for reductions in vascular inflammation, reductions in atherosclerotic
plaque progression, and improvements in plaque stability. Similarly, reductions in
serum CRP after cardiac rehabilitation may reflect a diminished non-specific systemic12
inflammatory condition (Rifai et al., 1999) or a reduced severity of vascular injury and
inflammation (Torzewski et al., 1998).
Only limited information is available regarding intervention-related changes in
serum CRP in coronary patients. One study reported reductions in serum CRP with
statin therapy in hyperlipidemic coronary patients (Strandberg et al., 1999), and
another study showed that aspirin therapy reduced MI risk most effectively in those
subjects within the highest quartile of circulating CRP levels prior to aspirin therapy
(Ridker et al., 1997). Significant reductions in serum TNF-a have been reported after
diet and exercise in obese diabetics (Katsuki et al., 1998). However, to our
knowledge, no study has examined whether serum CRP and TNF-a may be reduced
after cardiac rehabilitation in non-diabetic coronary patients. Because serum CRP and
TNF-a are shown to be independent risk factors for CAD (Ridker et al., 1998a, Ridker
et al., 1998b; Ridker et al., 1998c; Ridker et al., 2000; Tracy et al., 1997), it is
reasonable to speculate that reductions in serum CRP and proinflammatory cytokines
after cardiac rehabilitation might minimize future coronary events.
Statement of Purpose
The present study is ancillary to a larger parent study, which reported that the
first three months of cardiac rehabilitation program reduced insulin resistance,
abdominal obesity, and dyslipidemia in coronary patients with normal glucose
tolerance (Williams, 2000 in review). Using serum contingency samples that remain
stored frozen from the parent study, two separate approaches were taken for the13
present study. The first manuscript encompasses a cross-sectional analysis,
examining hormonal, metabolic, and behavioral disturbances associated with cortisol
metabolism, and the second manuscript encompasses a longitudinal analysis,
examining the effects of cardiac rehabilitation on reducing markers of inflammation in
26 non-diabetic coronary patients.
Aberrations in cortisol metabolism have long been implicated in the etiology of
abdominal obesity and insulin resistance. In addition, depression and anxiety are
associated with exaggerated cortisol secretion. However, no previous study has
clearly examined the complex associations of abdominal obesity-related insulin
resistance, depression, and cortisol in a group of subjects at risk of developing
diabetes. Thus, the first study sought to determine whether the serum cortisol
responses to oral glucose loading are associated with abdominal obesity, insulin,
glucose, and NEFA responses to oral glucose loading, and self-reported symptoms of
depression in a sample of non-diabetic coronary patients. We hypothesized that lower
cortisol responses to oral glucose loading would be associated with abdominal obesity,
higher serum insulin, glucose, and NEFA responses to oral glucose loading, and lower
depression scores.
Low-grade inflammatory conditions may be reduced after cardiac
rehabilitation in non-diabetic coronary patients because fat tissue secretes
proinflammatory cytokines that stimulate the production of CRP in the liver.
Therefore, we hypothesized that cardiac rehabilitation may reduce serum CRP and
TNF-a, in part, through reductions in fat mass. Thus, the second study sought to
determine whether the first three months of cardiac rehabilitation program would14
reduce serum CRP and TNF-ct in non-diabetic coronary patients. The secondary aim
was to determine whether the changes in serum CRP and TNF-a levels were
associated with the changes in body weight and waist circumference after cardiac
rehabilitation in our sample of non-diabetic coronary patients. We hypothesized that
greater reductions in abdominal obesity and body weight would be associated with
greater reductions in serum CRP and TNF-a after cardiac rehabilitation.15
CHAPTER 2
CORTISOL RESPONSES TO ORAL GLUCOSE ARE ASSOCIATED WITH
ABDOMINAL OBESITY, NON-ESTERIFIED FATTY ACID SUPPRESSION,
AND DEPRESSION IN NON-DIABETIC CORONARY PATIENTS
Kayoko Ogimoto and Daniel P. Williams
Submitted to International JournalofObesity and Related Metabolic Disorders,
Stockton Press, Hampshire, UK
September 2000, in review16
Ahstrt
The purpose of this study was to determine whether serum cortisol responses
to oral glucose loading are independently associated with abdominal obesity, insulin,
glucose, and NEFA responses to oral glucose loading, and self-reported symptoms of
depression in non-diabetic coronary patients. Our subjects included non-diabetic
coronary patients (19 men and 7 women, 43-82 years old, BMI 19.7-39.0 kg/m2) with
(N=14) or without (N=12) abdominal obesity according to gender-specific National
Heart, Lung, and Blood Institute criteria for critical waist circumferences. We
measured serum glucose, NEFA, insulin, and cortisol during a 2-hour oral glucose test
(at 0, 60, and 120 mm). We also assessed height, weight, waist circumferences, and
self-reported symptoms of depression. The mean serum NEFA response to oral
glucose loading was 36% higher (P=0.004) and the mean serum insulin response was
66% higher (P=0.023) in the patients with as compared to those without abdominal
obesity. However, the mean serum glucose (P0. 193) and cortisol (P0.066)
responses to oral glucose loading were not different between the patients with and
without abdominal obesity. Multiple regression analysis showed that the lower mean
cortisol responses were independently associated with abdominal obesity
(partial r=-0.52, P=0.008) and lower depression scores (partial r=0.48, P=0.015).
Moreover, lower mean cortisol responses were independently associated with higher
mean NEFA responses (partial r=-0.56, P=0.003) and lower depression scores (partial
r=0.44, P=0.028). We conclude that lower cortisol responses to oral glucose loading17
are associated with abdominal obesity, reduced NEFA suppression, and fewer
symptoms of depression in non-diabetic coronary patients.
Introduction
Glucocorticoids, like cortisol, have long been implicated in the etiology of
abdominal obesity and insulinresistance.1Cortisol excess, abdominal obesity, and
insulin resistance are common metabolic aberrations of Cushing' s Disease.' However,
individuals with abdominal obesity and insulin resistance but without Cushing's
Disease typically have normal or even low circulating cortisollevels.2'3Abdominal
obesity alone is characterized by greater degrees of cortisolsecretion4and a higher
density of glucocorticoid receptors in abdominal fat tissue5. Therefore, elevations in
cortisol turnover (i.e., increases in both production and metabolic clearance rates) may
be a common feature of abdominal obesity and insulin resistance in individuals
without Cushing's Disease.
Greater reductions in the morning cortisol response to oral glucose loading are
associated with greater degrees of abdominal obesity and with higher postload serum
glucoselevels.6Although these findings are consistent with abdominal obesity-related
increases in the metabolic clearance of cortisol, they do not address the potential for
abdominal obesity-related increases in cortisol production. Furthermore, the
assessment of glucose responses to oral glucose loading is somewhat limited because
it focuses more on skeletal muscle than fat tissue as important sites of peripheral tissue
resistance to insulin.718
Psychosocial stress, such as chronic depression, may result in hyperactivity of
the hypothalamic-pituitary-adrenal (HPA) axis, which, in turn, could account for an
overproduction of cortisol, leading to fat accumulation and to an impairment of insulin
action.8In addition, the normal insulin-mediated suppression of non-esterified fatty
acids (NEFA) after oral glucose loading is attenuated in individuals with abdominal
obesity9and can be used as a systemic index of impaired insulin action in fattissue.7
Furthermore, in individuals with normal glucose tolerance, higher circulating NEFA
levels are associated with a greater risk of developing impaired glucose or diabetes
that is independent of insulin resistance or insulin secretory defects.'°
To our knowledge, no previous study has examined the complex associations
among abdominal obesity-related insulin resistance, depression, and cortisol in a
group of subjects at risk of developing diabetes. Therefore, the purpose of this study
was to determine whether the serum cortisol responses to oral glucose loading are
associated with abdominal obesity, insulin, glucose, and NEFA responses to oral
glucose loading, and self-reported symptoms of depression in a sample of non-diabetic
coronary patients.
Materials and Methods
Subjects: The present study is ancillary to a parent study examining the effects
of cardiac rehabilitation on insulin resistance. Thus, the details of patient screening
and study inclusion/exclusion criteria are reported elsewhere.'In brief, 31 of 105
patient referrals met the study inclusion/exclusion criteria (primarily the presence of19
definitive CAD coupled with the absence of diabetes) and agreed to participate in the
parent intervention study. Of these 31 patients, five patients were not included in the
present data analysis. Three patients were excluded because their baseline oral
glucose tolerance test uncovered the presence of covert diabetes (2-hour postload
serum glucose levels200mgldL).'2Another patient was a diabetic who was missed
upon initial screening,and two other patients had missing data. Thus, the data
analyzed herein were derived from a sample of 26 non-diabetic coronary patients (19
men and 7 women).
Patient characteristics are described in detail elsewhere.11 In brief, the patients
ranged in age from 43 to 82 years, are well-educated (73% with college or graduate
school education), have a strong family history of myocardial infarction (88%), and
are predominantly former smokers(65%).There was only one patient who was a
current smoker at the time of present evaluation. The majority (77%) of the study
participants had been surgically treated with a coronary artery bypass or a
percutaneous transluminal coronary angioplasty and stent. The other patients (23%)
had been diagnosed with CAD but not surgically treated. All participants provided
written informed consent to the procedures before any data were collected. The study
was approved by the Institutional Review Boards at the university and the hospital.
Hormonal and Metabolic Outcomes: Fasting blood was drawn between 8-9
AM after a 12-hour fast. No vigorous physical activity was permitted on the morning
of the blood draw. After collecting the fasting blood samples, subjects consumed a
standard75g oral dose of glucose beverage, and subsequent blood draws were made20
at 1- and 2-hours after consumption of the glucose load. Blood samples were
collected in serum vacutainer tubes with gel clot activator. Whole blood samples were
allowed to remain at room temperature for 30 minutes to ensure complete blood
clotting. Afterwhich, clotted blood samples were centrifuged at 1500 g for 15 minutes
to separate the serum from the blood clot. After separation, the serum was either
immediately analyzed by the hospital clinical laboratory for glucose, lipid, and
lipoprotein-cholesterol levels, or aliquoted into specific, labeled vials for insulin, non-
esterified fatty acids (NEFA), and cortisol then stored frozen at 70°C for later
analysis by the study authors. The hospital clinical laboratory used Boehringer
Mannheim reagents (Indianapolis, IN) to assess serum glucose with a hexokinase
method'3and serum triglycerides with a peroxidase-coupled enzymaticmethod.'4
Fasting, 1-hour, and 2-hour postload serum insulin levels were assessed with a
human insulin-specific radioimmunoasay (Linco Research, St. Charles, MO). The
insulin-specific assay uses an antibody that does not appreciably cross-react with other
circulating insulin-like molecules. In our parent study, the interassay coefficient of
variation was 1.8% for a low-level serum insulin control and 3.0% for a high-level
serum insulin control11. Fasting, 1-hour, and 2-hour postload serum NEFA were
assessed with an enzymatic colorimetric method (Wako Diagnostics, Richmond, VA).
The interassay coefficient of variation was 4.2% for a pooled fasting serum NEFA
sample11. Fasting, 1-hour, and 2-hour postload serum cortisol levelswere measured
using a commercial radioimmunoassay (RIA) for human cortisol (Diagnostic Systems
Laboratories, Webster, TX). The interassay coefficient of variation was 4.0% for a21
low-level serum cortisol control that ranged from 69 to 152 nmol/L and 3.2% fora
high-level serum cortisol control that ranged from 414 to 690 nmol/L.
Body Composition: Height, weight, and waist circumferenceswere measured
according to the procedures described in the Anthropometric Standardization
Manual.15 Heightwas measured with a wall-mounted stadiometer, weight was
measured with a balance scale, and waist circumferenceswere measured a steel tape
measure. Waist circumferences of 102 cm for males and88 cm for females were
used to define abdominal obesity.'6
Questionnaires: Subjects visited the OSU Endocrine and Metabolism Lab to
complete a battery of questionnaires to assess their health behavior. Symptoms of
depression were assessed with the 20-item self-administered Center for Epidemiologic
Studies QuestionnaireAlcohol consumption was assessed with a Block Food
Frequency Questionnaire.'8 Study participants also completedan extensive medical
history questionnaire.
Statistical Analysis: Descriptive characteristics of study participants with and
without abdominal obesity were compared by independent t-tests for continuous
variables and by chi-square tests for categorical variables. Serum glucose, NEFA,
insulin, and cortisol responses to oral glucose loading were analyzed witha mixed-
factor repeated measures analysis of variance (RM ANOVA) to detect thepresence of
significant main effects of oral glucose loading and abdominal obesityas well as
significant interactive effects of abdominal obesity by oral glucose loading. To detect22
the presence of significant time-related trends across the three repeated measurements
(0, 1 h-, and 2h- after oral glucose), we partitioned the RM ANOVA into two
orthogonal trends (linear and quadratic). Simple linear and stepwise multiple
regression analysis were used to determine whether cortisol responses to oral glucose
loading were associated with abdominal obesity, insulin, glucose, and NEFA
responses to oral glucose loading, and with self-reported symptoms of depression.
Results are expressed as mean ± SD unless otherwise indicated. A level of
significance of P <0.05 was used for all hypothesis testing.
Results
Descriptive characteristics of study participants with and without abdominal
obesity are shown in Table 2.1. Patients with abdominal obesity were heavier, had
higher body mass indices, and had larger waist circumference than patients without
abdominal obesity. Fasting serum triglyceride levels were significantly higher in
patients with abdominal obesity as compared to patients without abdominal obesity
(P0.012). Patients with abdominal obesity reported somewhat higher mean
depression scores that approached, but did not reach statistical significance (P=0.092).
There were no statistically significant differences in such potential confounding
variables as age, gender, alcohol consumption, elapsed time between awakening and
fasting blood draw, smoking status, personal history of myocardial infarction,
"recovery" time from the cardiac surgery, event, or diagnosis, and the use of anti-23
depressant, anti-hypertensive, or statin medications between patients with and without
abdominal obesity.
Table 2.1. Descriptive characteristics of non-diabetic coronary patients (N26).
Variable Abdominal Obesity P-value
(+) (-)
(N = 14) (N = 12)
Age (years) 67.5±9.2
Height (cm) 170.9±6.8
Weight (kg) 91.0±10.6
BMI(kg/m2) 31.3±4.1
Waist Circumference (cm) 109.4±8.1
Fasting serum triglycerides (mmol/L)2.56±1.29
Alcohol Consumption (% kcal) 1.34±1.93
Awake-blood draw time (mm) 123.5 ± 52.9
Gender
63.6±9.0 0.283
171.5±11.0 0.874
72.1±11.2 <0.001
24.4±2.4 <0.001
88.2±9.5 <0.001
1.42±0.83 0.012
5.26±6.56 0.068
100.6±34.2 0.197
Male 42.3(11) 30.8(8) 0.495
Female 11.5 (3) 15.4 (4)
Depression(units) 10.3 ±8.9 4.8 ±7.0 0.092
Past smokers 34.6(9)a 34.6 (9) 0.555
History of MI 26.9 (7) 30.8 (8) 0.39 1
Early recovery' 38.5 (10) 38.5 (10) 0.473
Use of anti-depressants 11.5 (3) 7.7 (2) 0.578
Use of beta-blockers 19.2 (5) 30.8 (8) 0.116
Use of diuretics 15.4 (4) 7.7 (2) 0.473
Use of statins 34.6 (9) 23.1 (6) 0.462
BMI = body mass index.
Awake-blood draw time = elapsed time between awakening and fasting blood draw.
MI = myocardial infarction.
aincludes one current smoker.
b:less then 60 days since a cardiac surgery event or diagnosis.
Gender, past smokers, history of MI., early recovery, uses of anti-depressants, beta-
blockers, diuretics, and statins are expressed as % of total (N). All other variables are
expressed as mean ± SD.24
The serum glucose, NEFA, insulin, and cortisol responses to oral glucose
loading are shown by abdominal obesity in Figure 2.1. Significant quadratic (i.e.,
curvilinear) main effects of oral glucose loading were observed for serum glucose,
NEFA, and insulin (each with P<O.001), whereas a significant linear main effect of
oral glucose loading was observed for serum cortisol (P<O.001). Thus, interactive
effects of abdominal obesity by oral glucose loading were examined with quadratic
trends for oral glucose loading on the serum glucose, NEFA, and insulin responses and
with a linear trend for oral glucose loading on the serum cortisol responses.There were
no significant main or interactive effects of abdominal obesity on the serum glucose
response to oral glucose loading (PO.193). By contrast, there was a significant main
effect of abdominal obesity on the serum NEFA response to oral glucose loading, as
the patients with abdominal obesity had a 36% higher mean serum NEFA
concentration than those without abdominal obesity (P=O.004). There was also a
significant main effect of abdominal obesity on the serum insulin response to oral
glucose loading, as the patients with abdominal obesity had a 66% higher mean serum
insulin concentration than those without abdominal obesity (P=O.023). The main
effect of abdominal obesity on the serum cortisol response to oral glucose loading
approached but did not reach statistical significance (PO.066).25
Figure 2.1. Metabolic and hormonal responses to oral glucose loading.
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Serum glucose (A), NEFA (B), insulin (C), and cortisol (D)responses to a 75 g oral
glucose load in non-diabetic, coronary patients with (closed circles, N=14) and
without abdominal obesity (open circles, N=12).
Values are mean ± SD, and P-values are shown for the main effect.To determine whether our inability to detect significantly lower cortisol
responses to oral glucose loading in the patients with abdominal obesity was affected
by their trend to report somewhat higher symptoms of depression, we used multiple
regression analysis to predict cortisol responses to oral glucose loading from
abdominal obesity (O=no, and l=yes) and depression scores. As shown in Figure 2.2,
we found a complex interrelationship wherein abdominal obesity was associated with
lower cortisol responses to oral glucose loading, whereas higher depression scores
were associated with higher cortisol responses to oral glucose loading.
Figure 2.2. Association between mean serum cortisol response to oral glucose loading
and cortisol predicted from abdominal obesity and depression scores.
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Lower mean cortisol responses were independently associated with abdominal obesity
(partial r=-O.52, P=O.008) and lower depression scores @artial r=O.48, p=O.Ol5) in the
non-diabetic coronary patients.27
To determine the main metabolic and behavioral determinants of the cortisol
responses to oral glucose loading, we also used stepwise multiple regression to predict
the cortisol responses to oral glucose loading from abdominal obesity, the insulin,
glucose, and NEFA responses to oral glucose loading, and from depression scores. As
shown in Figure 2.3, we found another complex interrelationship wherein reduced
NEFA suppression after oral glucose loading was associated with lower cortisol
responses to oral glucose loading, whereas higher depression scores were associated
with higher cortisol responses to oral glucose.
Figure 2.3. Association between mean serum cortisol response to oral glucose loading
and cortisol predicted from mean serum NEFA responses and depression scores.
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Lower mean cortisol responses were independently associated with higher mean
NEFA responses (partial r=-O.56, p=O.003) and lower depression scores (partial
r=O.44, P=O.028) in the non-diabetic coronary patients.28
Discussion
The present findings extend the determinants of serum cortisol responses to
oral glucose loading from abdominal obesity and skeletal muscle insulinresistance6to
now include symptoms of depression and fat tissue insulin resistance. Our findings
that higher depression scores are associated with higher cortisol responses to oral
glucose loading are consistent with the report that men with symptoms of anxiety and
depression have a blunted inhibition of cortisol secretion bydexamethasone.19Thus,
depression, anxiety, or social isolation may alter the 1-IPA axis to stimulate cortisol
production. The present study is likewise consistent with earlier reports of
associations of depression with insulinresistance20and coronary arterydisease.2'
Our finding that reduced NEFA suppression after oral glucose loading was a
stronger correlate of lower cortisol responses to oral glucose loading than either
glucose or insulin responses to oral glucose loading highlights the importance of fat
tissue as a site of peripheral tissue resistance to insulin. Because cortisol inhibits the
antilipolytic effect of insulin in fattissue,22it is plausible that an elevated metabolic
turnover of cortisol in fat tissue could result in higher circulating NEFA levels.
Moreover, one potential metabolic consequence of elevated postprandial NEFA, due
to an increased lipolysis, may be hypertriglyceridemia. A greater NEFA release from
adipocytes, in turn, would stimulate hepatic production of very low-density
lipoprotein, thereby increasing serum triglyceride concentrations. In the present study,
patients with abdominal obesity had higher serum NEFA and higher fasting serum
triglyceride levels as compared to patients without abdominal obesity. Furthermore,29
hypertriglyceridemia would increase triglyceride delivery to the lipid core of
atheroscleroticplaques,23which renders plaques softer and more vulnerable to rupture,
thereby precipitating coronaryevents.24
Another important finding of the present study is the trend for reporting
somewhat higher depression scores in the patients with abdominal obesity, which may
have obscured our ability to detect lower cortisol levels in the patients with abdominal
obesity. For instance, we could only detect a lower cortisol response to oral glucose
loading in the patients with abdominal obesity when depression was held constant.
Previous studies have likewise reported lower cortisol responses to oral glucose in
individuals with abdominalobesity.6'25A higher density of glucocorticoid receptors
was reported in abdominal visceral adipocytes as compared to adipocytes in other
regions of thebody.5Thus, a depression-related increase in the production of
cortisol'9coupled with an abdominal obesity-related increase in the metabolic
clearance of cortisol may help to explain the independent yet oppositely directed
associations among cortisol responses to oral glucose loading, depression, and
abdominal obesity observed herein.
By contrast to our findings, Troxler et al. reported that elevated morning
cortisol during oral glucose loading was associated with a greater severity of
atherosclerosis in coronarypatients.26However, their association between elevated
morning cortisol levels and a greater number of atherosclerotic coronary lesions is
likely confounded by the higher levels of cigarette smoking behavior among those
patients with more coronary lesions. Nicotine in cigarette smoke increases ACTH and
cortisolsecretion.27By contrast to the patients in Troxler et al.'s study, who, on30
average, smoked 7 to 17 cigarettes per day, only one of our 26 patients was a current
smoker.
Several limitations of the study should be addressed. First, the small sample
size of predominantly male patients may limit the ability to extrapolate our findings to
female patients. However, we minimized the potential confounding effect of gender
on abdominal obesity-related insulin resistance by using gender-specific criteria for
abdominalobesity.16Second, we used anthropometry to assess abdominal obesity,
which is more accurately assessed by computedtomograhpy.28However, the use of
waist circumferences to assess abdominal obesity in the present study is a valid,
reliable, and practical surrogate for expensive imaging techniques that require
exposure to ionizingradiation.29Lastly, with regard to understanding the functional
significance of cortisol, single measurements of serum cortisol are not as
mechanistically insightful as determining cortisol production and metabolic clearance
rates.
30
In conclusion, serum cortisol responses to oral glucose loading have a complex
interrelationship with abdominal obesity, NEFA suppression, and self-reported
symptoms of depression in non-diabetic coronary patients. Our data suggest that
lower cortisol responses to oral glucose loading are associated with abdominal obesity,
reduced NEFA suppression, and fewer symptoms of depression. Future prospective
studies should determine whether psychosocial risk factors, like depression and
anxiety, increase cortisol production, whether increases in cortisol production act
synergistically with a positive energy balance in the development of abdominal31
obesity, and whether increases in abdominal obesity lead to increases in cortisol
metabolism and insulin resistance.32
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Abstract
C-reactive protein (CRP) is a marker of inflammation that is associated with
increased risk for recurrent events in coronary patients. However, no study has
examined whether circulating levels of CRP may be reduced after cardiac
rehabilitation. Thus, we measured serum levels of CRP and the proinflammatory
cytokine, tumor necrosis factor-a (TNF-a), before and after the first three months of
cardiac rehabilitation in 26 non-diabetic coronary patients (19 men and 7 women).
We found 25 to 43% reductions in the median ± interquartile range of serum CRP
after cardiac rehabilitation in the total sample of patients (N=26, P=0.012). The
cardiac rehabilitation-related reductions in serum CRP remained statistically
significant even after excluding 4 patients who initiated statin therapy (N=22,
P=0.006), or 6 patients with serum CRP above the subclinical acute inflammatory
threshold of 10 mg/L (N=20, P=0.040). By contrast, we found nonsignificant changes
in the median ± interquartile range of serum TNF-a after cardiac rehabilitation, which
ranged from 6 to +1% (N=26, P=0.869). After cardiac rehabilitation, reductions in
serum CRP were correlated with reductions in waist circumferences (r=0.39,
P=0.049). Cardiac rehabilitation may reduce the severity of low-grade inflammatory
conditions, in part, through reductions in waist circumference in non-diabetic coronary
patients.37
Introduction
Inflammation is an integral part of the processes of atherothrombosis.'
Atherosclerosis is initiated by endothelial injury, which leads to a series of
inflammatory responses including a release of monocyte-derived cytokines, such as
tumor necrosis factor-a (TNF-a), interleukin- 1 (IL-i) and interleukin 6 (IL-6) and
other proinflammatory substances, which promote systemic inflammation and the
synthesis of such hepatic acute phase proteins as C-reactive protein(CRP).2Local
inflammation in the vascular endothelium has been implicated in the erosion of the
fibrous cap of advanced atherosclerotic plaques, which contribute to plaque instability
and plaque rupture.'
CRPis a circulating acute phase protein, which may increase several hundred
fold3in response to tissue injury, infection, orinflammation.4However, relatively
modest 2 to 3-fold elevations in serum CRP that are well below the acute-phase
inflammatory threshold increase the risk for future coronary events in patients with a
prior myocardialinfarction,5in patients withstable6and unstableangina68and in
patientswhohave undergone coronary artery bypass graftsurgery.9Thus, it is likely
that a more chronic state of low-grade inflammation increases the risk for recurrent
coronary events. Furthermore, the predictive value of low-grade elevations inCRP
are independent of other coronary risk factors including dyslipidemia'°" and
subclinicalCVD.'2
In addition to their direct role in the pathogenesis of atheroma, circulating
levels of bothCRP6' 13-16andTNF-a17"8are elevated in obesity, and elevated serum38
TNF-a is, like CRP, an independent risk factor for recurrent coronary events in
coronary patients.'9 Significant reductions in serum TNF-a have been reported after
diet and exercise in obese diabetics.2° However, to our knowledge, no study has
examined whether serum CRP and TNF-a may be reduced after cardiac rehabilitation
in non-diabetic coronary patients.
Thus, we sought to determine whether the first three months of cardiac
rehabilitation program would reduce serum CRP and TNF-a in non-diabetic coronary
patients. The secondary aim was to determine whether the changes in serum CRP and
TNF-a levels were associated with the changes in body weight and waist
circumference after cardiac rehabilitation in our sample of non-diabetic coronary
patients.
Material and Methods
Subjects: A nurse case manager screened 105 consecutive physician-referred
patients to an outpatient, hospital-administered cardiac rehabilitation program between
April of 1998 and March of 1999. Of the 105 referrals, 48 were eligible non-diabetic
coronary patients, and 31 patients agreed to participate in the study. Because diabetics
have higher circulating cytokine mediators and acute phase protein markers of
inflammation,2 three undiagnosed diabetics with baseline 2-hour postloadserum
glucose levels200 mg/dL2' were excluded along with one patient who was a
diabetic screening error, and another patient who dropped out of the intervention.
Thus, the data analyzed herein were derived from a sample of 26 non-diabetic39
coronary patients (19 men and 7 women). All female patients were postmenopausal
women, and five of them were undergoing oral hormone replacement therapy (HRT)
throughout intervention.
The patients ranged in age from 43 to 82 years, were well-educated (73% with
college or graduate school education), had a strong family history of myocardial
infarction (88%), and were predominantly former smokers (65%). One patient who
was a smoker at the baseline evaluation quit smoking during the intervention.
Seventy-seven percent of the study participants had undergonea surgery (65% with
coronary artery bypass graft surgery and 12% with percutaneous transluminal
coronary angioplasty and stent procedures), and 23% of the patients had been
diagnosed with coronary artery disease (CAD) but not surgically treated. All
participants provided written informed consent to the procedures, whichwere
approved by the Institutional Review Boards at the university and the hospital.
Cardiac Rehabilitation Program: A detailed description of the cardiac
rehabilitation program is described elsewhere in a report on a sub-sample of 20
patients with normal glucosetolerance.22In brief, the program follows the risk factor
reduction goals outlined by the American HeartAssociation,23the lipid treatment
goals of the National Cholesterol Education Program(NCEP),24and the blood
pressure treatment goals of the Joint NationalCommittee.25The exercise program
consisted of 36 supervised classes (3 classes I week x 12 weeks) of moderate-intensity
(approximately 60-70% of maximal heart rate reserve) aerobic activity with the
duration gradually increased to 40 mm per session after the first 4-6 weeks. Exercise40
class attendance averaged 85 ± 10% and ranged from 64-97%. A dietitian instructed
every patient to adopt a step II American Heart Association (AHA)diet.24Patients
were also encouraged to attend a formal group support class that was facilitated by a
social worker two times per month, and they were also given a self-directed
educationalworkbook26for psychological stress management.
Blood sampling and biochemical assays: Before and after the three-month
cardiac rehabilitation program, subjects reported to the lab between 8-9 AM after a 12-
hour fast for a fasting blood draw. No vigorous physical activity was permitted on the
morning of the blood draw. Blood samples were collected in serum vacutainer tubes
with gel clot activator. Whole blood samples were allowed to remain at room
temperature for 30 minutes to ensure complete blood clotting. Afterwhich, clotted
blood samples were centrifuged at 1500 g for 15 minutes to separate the serum from
the blood clot. After separation, the serum was aliquoted into specific, labeled vials
for each analyte and stored frozen at 70°C for later analysis.
An enzyme-linked immunosorbent assay (ELISA) was used to measure fasting
serum CRP levels (Diagnostic Systems Laboratories, Webster, TX) and fasting serum
TNF-a levels (R&D Systems, Minneapolis, MN). The ELISAs are newly developed,
highly sensitive commercial assay kits. However, we modified the dilution protocol
for serum CRP kit. Rather than indiscriminantly diluting every serum sample 1:500,
we initially diluted every sample 1:50, which has a detectable range of 0.5 to 25 mg/L.
Any sample below 0.5 mg/L was reanalyzed at a 1:5 dilution, which reduced the lower
limit of detection to 0.05 mg/L. Any sample above 25 mgIL was reanalyzed at a 1:50041
dilution, which increased the upper limit of detection to 250 mg/L. The interassay
coefficient of variation was 5.2% for a low-level serumCRPcontrol that ranged from
1.5 to 1.6 mg/L, 3.0% for a high-level serum CRP control that ranged from 12.0 to
13.2 mg/L, and 4.2% for a mid-range serum TNF-ct control that ranged from 2.7 to 5.0
pg/mL.
Body Composition: Height, weight, and body circumferences were measured
before and after the three-month cardiac rehabilitation program according to
standardized procedures.27 Height was measured with a wall-mounted stadiometer,
and weight was measured with a balance scale. Circumferences were measured with a
steel tape measure at the waist and hip sites.
Questionnaire: Patients completed an extensive medical history questionnaire
including current medications, personal medical history of acute and chronic illnesses
(including the dates of the most recent CAD event, surgery, or diagnosis), family
history of CAD and diabetes, and smoking behavior. The elapsed time between the
most recent injurious CAD event or surgery and the beginning of the cardiac
rehabilitation intervention was recorded for each patient to examine the potential
confounding influence of "recovery" time on cardiac rehabilitation-related changes in
serum CRP and TNF-a levels. Because the majority of patients (N=20) had recovery
time60 days, the presence or absence of "early recovery" was coded as a categorical
variable.42
Statistical Analysis: The distributions of serum CRP and TNF-a levels were
positively skewed. Thus, non-parametric tests were used to determine the role of
chance. For instance, comparisons of baseline serum CRP and TNF-a between groups
of patients with and without past smoking behavior, family history of CAD and
diabetes, the use of selected medications, and an "early" recovery from the most recent
CAD event, surgery, or diagnosis were made with a Mann-Whitney U test. A
Wilcoxon signed rank test was used to compare serum concentrations of CRP and
TNF-a before and after cardiac rehabilitation. Because reductions in circulating CRP
levels have been reported after beginning statintherapy,28the comparison of serum
CRP levels before and after cardiac rehabilitation was also made in a sub-sample of 22
patients with stable statin therapy throughout the study. To control for the potential
confounding effect of subclinical inflammatory conditions, serum CRP levels before
and after cardiac rehabilitation were also compared in another sub-sample of 20
patients with baseline CRP levels <10 mgIL, which is an accepted clinical standard for
the absence of significant inflammatory disease. Moreover, because the HRT has
been reported to increaseCRP,29the comparison of serum CRP levels before and after
cardiac rehabilitation was made in a sub-sample of 19 patients with stable statin
therapy that further exclude female patients with ITRT. Changes in body composition
after cardiac rehabilitation were normally distributed and were therefore assessed with
a paired t-test. Intercorrelations between cardiac rehabilitation-related changes in
serum CRP, serum TNF-a, and body composition were examined using Spearman's
rank order correlation. A value of P <0.05 was considered statistically significant for
all hypothesis testing.43
Results
None of the selected potential confounding variables such as smoking status,
medical history (family history of myocardial infarction or diabetes, personal history
of myocardial infarction), the use of selected medications (statins, aspirin, diuretics,
beta-blockers, calcium-channel blockers, and ACE-inhibitors), or the presence of
"early recovery" affected baseline serum levels of CRP and TNF-a (P0. 102, data not
shown).
Serum levels of CRP before and after cardiac rehabilitation are shown in
Figure 3.1. Figure 3.1 A shows 25% to 43% reductions in the median ± interquartile
range of serum CRP levels after cardiac rehabilitation in the total sample of 26
patients (P=0.012). There were 4 patients who began statin therapy during cardiac
rehabilitation. Thus, changes in serum CRP levels after cardiac rehabilitation were
also examined in the sub-sample of 22 patients with stable statin therapy. As shown in
Figure 3.1 B, there were 21% to 43% reductions in the median ± interquartile range of
serum CRP levels after cardiac rehabilitation in patients with stable statin therapy
(P=0.006). There were three female patients within the sub-sample of stable statin
therapy who were on HRT. We also observed 26% to 40% reductions in the median ±
interquartile range of serum CRP levels after cardiac rehabilitation in the sub-sample
of 19 patients with stable statin therapy that further exclude three female patients with
HRT (P=0.016, data not shown). There were 6 patients with serum CRP levels above
the subclinical acute inflammatory threshold of 10 mg/L. Thus, changes in serum
CRP levels after cardiac rehabilitation were further examined in the sub-sample of 2044
patients with serumCRP <10mg/L. As shown in Figure 3.1C, there were 24% to
59% reductions in the median ± interquartile range of serumCRPlevels after cardiac
rehabilitation in patients with normalCRPlevels (P0.040).
Figure 3.1. Fasting serum C-reactive protein levels before and after three months of
cardiac rehabilitation.
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(A) total sample of 26 non-diabetic coronary patients, (B) sub-sample of 22 patients
with stable statin therapy, and (C) sub-sample of 20 patients with C-reactive protein
levels <lOmg/L. Values are expressed as median ± interquartile range.45
By contrast, Figure 3.2 shows nonsignificant changes in the median ±
interquartile range of serum TNF-a levels after cardiac rehabilitation, which ranged
from 6% to +1% in the total sample of 26 patients (P=O.869).
Figure 3.2. Fasting serum tumor necrosis factor-a levels before and after three
months of cardiac rehabilitation in non-diabetic coronary patients (N=26).
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Values are expressed as median ± interquartile range.46
Changes in body composition after cardiac rehabilitation are shown in Table
3.1. After cardiac rehabilitation, waist (P=0.009) and hip (P=0.0 18) circumferences
were significantly reduced, whereas body weight remained unchanged (P=0. 167).
Table 3.1. Changes in body composition after cardiac rehabilitation in non-diabetic
coronary patients (N=26).
Variable Before After P-value
Height(cm) 171.2±8.8 171.2±8.8 0.738
Weight (kg) 82.3± 14.4 81.5± 13.8 0.167
BMI(kg/rn2) 28.1 ± 4.8 27.8±4.7 0.19 1
Waist circumference (cm)99.6±13.8 98.2±13.6 0.009
Hip circumference (cm) 103.7±9.0 102.2±7.8 0.018
BMI = body mass index.
Values are expressed as mean ± SD.
Table 3.2 shows Spearman correlations between changes in serum CRP, serum
TNF-a, and body composition after cardiac rehabilitation. Cardiac rehabilitation-
related changes in serum CRP and waist circumference were intercorrelated, as the
largest reductions in waist circumferences were correlated with the largest reductions
in serum CRP (r=0.39, P0.049). By contrast, changes in waist circumference were
not correlated with changes in serum TNF-a levels (r=-0.01, P=0.947). Furthermore,
despite its role as a cytokine mediator of the acute phase response, the correlation
between changes in serum TNF-a and serum CRP approached but did not reach
statistical significance (r=0.32, P=0. 111).47
Table 3.2. Intercorrelation matrix of changes in circulatory markers of inflammation
and body composition after cardiac rehabilitation in non-diabetic coronary patients
(N=261.
Variable A CRP A TNF-a A Weight A Waist Circ. A Hip Circ.
ACRP 1.00
A TNF-a 0.32 1.00
(pO.11 1)
A Weight 0.05 -0.29 1.00
(p=O.8O2) (p=O.l51)
A Waist Circ.0.39* -0.01 0.75*
(p=O.049) (p=O.947) (p<O.001)
AHipCirc.-0.18 -0.08 0.66*
(p=O.39O) (p=O.7l7) (p<O.001)
aSpearman rank-order correlation coefficients.
Waist Circ. = Waist circumference.
Hip Circ. = Hip circumference.
P<0.05.
Discussion
1.00
0.36 1.00
(p=O.O67)
To our knowledge, this is the first study to report significant reductions in
serum CRP levels after cardiac rehabilitation in non-diabetic coronary patients. The
observed correlation between changes in serum CRP and waist circumferences,as
well as the absence of associations between elevated serum CRP and "early recovery"
from surgery or other confounding effects of medication use, favor the interpretation
that the reduction in serum CRP is due to the effects of cardiac rehabilitation.
Furthermore, our ability to detect significant reductions in serum CRP after cardiac48
rehabilitation in the sub-sample of 20 patients withCRPlevels <10 mg/L also reduces
the likelihood that acute subclinical inflammatory conditions or the natural time course
of the recovery from surgery or acute coronary events may explain the observed
reductions in serumCRP.
There is one recent report of a 35% reduction in mean serumCRPlevels after
6 months of moderate-intensity exercise in subjects at high risk forCAD,3°although it
did not reach statistical significance (P=0.120). Thus, our ability to detect 25%-43%
reductions in the median ± interquartile range of serumCRPafter only 3 months of
diet, exercise, and stress reduction in non-diabetic coronary patients emphasizes the
importance of using non-parametric statistics to assess intervention-related changes in
non-normally distributed outcomes like serumCRP.
Because previous studies using highly sensitiveCRPassays likely did not use
multiple dilutions to detect exactCRPlevels for those patients with elevatedCRP
values, our data for those patients withCRPlevels < 10 mg/L are most comparable to
previous reports of serumCRPin coronary patients. Baseline levels of serum CRPin
our sub-sample of 20 patients withCRP < 10mg/L (median = 3.6 mg/L, interquartile
range = 2.0-7.8 mgIL) were similar to those of coronary patients reported previously,
wherein the median was approximately 3mg/L.31
The finding of a correlation between changes in serumCRPand changes in
waist circumferences may help to provide some insight into the potential mechanisms
whereby cardiac rehabilitation may help to reduce serumCRPlevels. For instance,
adipose tissue synthesizes a variety of pro-inflammatory cytokines, including49
TNF-a,34IL-i, andIL-6.35Thus, reductions in waist circumference following cardiac
rehabilitation may result in a reduced mass action of adipocyte-derived cytokines that
stimulate hepatic CRPproduction.36'37Our finding that reductions in waist
circumference were correlated with reductions in serum CRP but not with reductions
in serum TNF-o suggest that future studies should assess the effects of cardiac
rehabilitation and/or body composition changes on serum IL-i and IL-6. Moreover,
because subcutaneous adipose tissue actively secretes IL-6 but not TNF-a invivo,35
IL-6 may be the main endocrine mediator of adipocyte-derived increases in hepatic
CRP production.
The present finding of no change in serum TNF-a is, nevertheless, somewhat
unexpected. Circulating TNF-a levels were reduced after 4 weeks of diet and exercise
in obese patients withNIDDM.2°However, the obese diabetic patients in thatstudy2°
also experienced a 5-fold greater reduction in mean body mass index (BMI) as
compared to our non-diabetic coronary patients whose mean BMI was
nonsignificantly reduced by 1% (P=O.191). Thus, larger reductions in body weight or
body fat than those observed herein may be needed to detect significant reductions in
serum TNF-a.
Alternatively, our finding of nonsignificant reductions in serum TNF-a after
cardiac rehabilitation may also reflect the limitation of measuring systemic serum
TNF-a that could be derived from activatedmacrophages,38endothelialcells,39
atheroscleroticplaques,4°or excessive amounts of visceral adiposetissue.34Thus, if
TNF-a primarily functions by a paracrine/autocrine rather than an endocrine route of50
delivery,35'4' then intervention-related changes in local tissue production and secretion
of TNF-a may be more informative than systemic studies of changes in total serum
TNF-a concentrations. Despite its role as a cytokine mediator of the acute phase
response, the correlation between changes in serum TNF-a and serumCRP
approached but did not reach statistical significance (r=O.32, P=O.111). Although
others have reported strong cross-sectional correlations between serumCRPand TNF-
18our results suggest that reductions in serum TNF-a are not required to observe
reductions in serum CRP.
Our finding of reduced serumCRPafter cardiac rehabilitation may have
important clinical implications. For instance, cardiac rehabilitation can result in a
two-fold reduction in recurrent cardiac events despite only modest reductions in
atheroscleroticprogression.42The present reduction in serum CRP raises the
possibility that cardiac rehabilitation may reduce the risk for recurrent events by
reducing the chronic low-grade inflammation that may result from and possibly
contribute toatherothrombosis.43
Our findings require confirmation in an experimental comparison of cardiac
rehabilitation vs. a "usual care" control group to more definitively determine causality.
Second, the potential for selection and referral bias and small sample size, particularly
women (N=7), may limit the generalizability of our findings. While HRT may have
caused elevations inCRP levels,29we did not have enough statistical power to detect
potential interaction between cardiac rehabilitation and HRT in our female patients.
Third, we used anthropometry to assess changes in abdominal fat, which can be more
accurately assessed by computedtomograhpy.44However, the use of waist51
circumferences to assess abdominal obesity in the present study is a valid, reliable, and
practical surrogate for expensive imaging techniques that require exposure to ionizing
radiation.45
In conclusion, cardiac rehabilitation may reduce the severity of low-grade
inflammatory conditions, in part, through reductions in waist circumference in non-
diabetic coronary patients. With experimental confirmation, the present findings may
help to broaden the mechanistic basis for how cardiac rehabilitation may reduce the
risk for future events in coronary patients.52
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CHAPTER 4
CONCLUSION
Overwhelming evidence supports the health benefits of cardiac rehabilitation
(Haskell et al., 1994, Ornish et al., 1998). However, physician referrals and patient
enrollments remain low (AHA, 1994). The high prevalence of CAD eventrecurrence
and the substantial economic burden of the nearly 12 million Americans whoare
currently living with CAD necessitate an improvement in the quality and delivery of
cost-effective, secondary preventive health care. While most studies have been
focusing on atherosclerotic risk factor modification as the measure of effective cardiac
rehabilitation programs (Haskell et al., 1994, Omish et al., 1998), it is also imperative
to understand the pathophysiological mechanisms for disease progression and event
precipitation. Thus, our approach was to focus on the importance of managing the
underlying neuroendocrine disorders, insulin resistance and chronic low-grade
inflammation, that contribute to disease progression and event precipitation.
Abdominal obesity is a part of insulin resistance syndrome that is closely
linked to increased risk of coronary artery disease (CAD) (Després, 1997). Because
fat tissue acts as an endocrine target and an important source of hormone production,
increased metabolism or production of chemical messengers in fat tissue, suchas
NEFA, may result in metabolic perturbations that contribute to the occurrence and
recurrence of coronary events. Psychosocial stress, such as chronic depression, may
result in hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis, which, in
turn, could account for an overproduction of cortisol, leading to fat accumulation and58
to an impairment of insulin action (Rosmond et al., 1998). However, the complex
interactions of abdominal obesity-related insulin resistance, depression, and cortisol in
a group of subjects at risk of developing diabetes are not clear. Thus, the first study, a
cross-sectional analysis, sought to determine whether serum cortisolresponses to oral
glucose loading are associated with abdominal obesity, non-esterified fatty acid
(NEFA) suppression, and self-reported symptoms of depression in 26 non-diabetic
coronary patients.
Results of the first study showed that lower cortisol responses to oral glucose
loading was associated with abdominal obesity, higher serum NEFA and insulin
responses to oral glucose loading, and lower depression scores (P0.028). Our
findings confirm recent reports that fat tissue is an important site of peripheral
resistance to insulin (Abbasi, 2000; Charles, 1997) and that serum NEFA levels, rather
than traditionally measured serum glucose levels, may be a more relevant
physiological marker of insulin resistance in coronary patients. Persistent elevations
in circulating NEFA due to fat tissue insulin resistancemay provide, in part, an
important mechanistic link between abdominal obesity-related insulin resistance and
CAD events. In addition, our data support the theory that the metabolic turnover of
cortisol may be enhanced in patients with abdominal obesity. Future prospective
studies should determine whether psychosocial risk factors, such as depression and
anxiety, increase cortisol production, whether increases in cortisol production act
synergistically with a positive energy balance in the development of abdominal
obesity, and whether increases in abdominal obesity lead to increases in cortisol
metabolism and insulin resistance.59
C-reactive protein (CRP) is a marker of low-grade inflammation that is
associated with increased risk for recurrent events in coronary patients (Ridker et al.,
1998, Tracy et al., 1997). Fat tissue also secretes proinflammatory cytokines that
stimulate hepatic production of CRP (Mohamed-Ali et al., 1997). However, to our
knowledge, no study has examined whether serum CRP and the proinflammatory
cytokine, tumor necrosis factor-a (TNF-a), may be reduced after cardiac
rehabilitation in non-diabetic coronary patients. Thus, the second study, an
intervention study, sought to determine whether the first three months of cardiac
rehabilitation would reduce serum CRP and TNF-a in our non-diabetic coronary
patients (N=26).
Results from the intervention study showed significant reductions in serum
CRP levels (P=O.O 12) that were associated with reductions in waist circumferences
after cardiac rehabilitation (r0.39, P=O.049). However, changes in serum TNF-a
levels after cardiac rehabilitation were nonsignificant (P=O.869). Based on the
intervention study, we conclude that cardiac rehabilitation may reduce the severity of
low-grade inflammatory conditions, in part, through reductions in waist circumference
in non-diabetic coronary patients.
The findings of the present study provide important clinical implications. For
instance, future interventions should specifically target and aggressively treat patients
for greater reductions in fat mass, better management of depression, and improved
control of low-grade inflammation to maximize the health benefits of cardiac
rehabilitation. Moreover, continuous efforts should be made among health
professionals for better understanding the pathophysiological mechanisms of60
abdominal fat gain and loss, peripheral tissue resistance to insulin, and atherosclerotic
plaque vulnerability and stability.61
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Appendix A: Institutional Review Board Approval
GOOD
= SAMARITAN
= HOSPITAL CORVALLIS
36CC NW Samaritan Drive, P.O. Box 1068, Corvallis, Oregon 97339 (541)757-5111
February 23, 1998
Daniel P. Williams, PhD
Oregon State University
120 Women's Building
Corvallis, OR 97331-6802
Dear Dr. Williams:
REF: Cardiac Rehabilitative Effects on Insulin Resistance in Coronary Artery Diseased Patients
This is to inform you that the revised informed consent document for your proposed study was
reviewed by the IRB committee today. The committee has accepted the changes as presented. They
accepted your justification for using one consent that includes an explanation of the separate evaluation
processes for blood samples taken.
They also support your plan to proceed with the study as you have outlined, including theadditional
changes to the original protocol: (1) a substitution in the type of tool used to assess dietary intake,the
addition of two new tools for assessing psychosocial stress, and the addition of bioelectrical impedance
measurements for estimating body composition; (2) the addition of two psychosocial stress assessment
tools; and (3) use of an additional technique (bioelectrical impedance) that is capable of discriminating
between fat and fat-free tissues.
The committee will expect to receive periodic reports of the study's progress.
Sincerel
Richarance, MD
Chair, s/mB Committee
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INSTITLTrIONAL REVIEW BOARD FOR THE PROTECTION OF HUMAN SUBJECTS
S
OREGON STATE UNIVERSITY
Report of Review
TO: Daniel P. Williams, ExSS
RE: Cardiac rehabilitative effects on insulin resistance in coronary artery diseased patients.
The referenced project was reviewed under the guidelines of Oregon State University's
Committee for the Protection of Human Subjects and the U.S. Department of Health and Human
Services. The committee has approved your application. The approval of this application
expires upon the completion of the project or one year from the approval date, whichever is
sooner. The informed consent form obtained from each subject should be retained in
program/project's files for three years beyond the end date of the project.
Any proposed change to the protocol or informed consent form that is not included in the
approved application must be submitted to the IRB for review and must be approved by the
committee before it can be implemented. Immediate action may be taken where necessary to
eliminate apparent hazards to subjects, but this modification to the approved project must be
reported immediately to the IRB.
Date:
Warren N. Suzuki,
Committee for the Protection of Human Subjects
(Education, 7-6393, suzukiw@ccmail.orst.edu)RESEARCH OFFICE
S
OcoN
STATE
UNIVERSITY
12 X.cir Askiinlstri*Ioa Bldg.
c Og
97331.2140
Telephone
54! 7370670
F.x
54,! 7373093
lnten,et
ma,y.nunn@oon.edu
RECEIVED
MAR5 1999
RESEARCH
OFFiCE
Principal lnvestigator Daniel Williams
The following project has been approved for continuation under the
guidelines of Oregon State University's Committee for the Protection
of Human Subjects and the U.S. Department of Health and Human
Services:
Principal Investigator(s):Daniel Williams
Student's Name (if any):
Department: Exercise and Sport Science
Source of Funding:
Project Title: Cardiac Rehabilitative. Effects on Insulin
Resistance in Coronary Artery Diseased
Patients (continuation)
Comments: Please provide informationon thenumber
of women excluded from participation and
the reasons for exclusion.
This approval for continuation is valid for
one year from the date of this letter.
Sincerely,
Warren N. Suzuki, Chair 0 Date:..('I
Committee for the Protection of Human Subjects
(Education, x7-6393, suzukiw@ccmail.orst.edu)
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Appendix B: Informed Consent
OREGON STATE UNIVERSITY ENDOCRINE AND METABOLISM
LABORATORY
Informed Consent Document
A. Title of Research Project
Cardiac rehabilitative effects on insulin resistance in patients with coronary artery
disease.
B. Investigator
Daniel P. Williams, Ph.D.
C.Purpose of the Research Project
Prior studies have demonstrated that regular participation in a cardiac rehabilitation
program that includes increases in physical activity, reductions in dietary fat intake,
reductions in smoking behavior, and improvements in stress management favorably
reduce the risk for heart attacks in patients with coronary artery disease (CAD). Most
cardiac rehabilitation programs encourage reductions in blood cholesterol, blood
pressure, and body weight to reduce the risk for heart attacks in patients with CAD.
However, more recent studies suggest that reductions in body fat around the abdomen
as well as reductions in blood insulin levels after eating may be "newer" risk factors,
which if properly controlled, may result in improved prevention of heart attacks in
patients with CAD. Therefore, the present study will determine the effectiveness of
the first three months of the cardiac rehabilitation program at Good Samaritan for 1.)
reducing body fat around the abdomen, and 2.) reducing blood insulin levels after
eating. Because it would be difficult to get everyone to eat the same amountoffood
within the same amount of time, the present study will draw blood samples (for
measuring insulin levels) once before and twice after drinking a sugar solution.
Finally, because the present cardiac rehabilitation program will encourage increases in
physical activity, reductions in dietary fat intake, a stop to smoking (for all smokers),
and improvements in stress management, the present study will also be measuring
physical activity levels, dietary intake, smoking behavior, and two possible
components of stress (symptoms of depression and feelings of hostility), so that the
extent to which positive changes in behavior may help to reduce body fat around the
abdomen as well as reduce blood insulin levels after drinking a sugar solution may be
better understood in patients with CAD.76
D.Procedures
I have received an oral and written explanation of this study, and I understand that I
was selected to participate in this study because I have been diagnosed with coronary
artery disease. In addition, I was selected because I have no previous history of
diabetes, and I am not taking insulin or oral medications aimed at controlling my
blood sugar. Furthermore, I understand that as a participant in this study the following
things will happen as a result of my participation in the study:
SUGAR SOLUTION TEST AT GOOD SAMARITAN. On the day of the sugar
solution test before and after the three-month cardiac rehabilitation program, I will
arrive at the Good Samaritan clinical laboratory in the morning, without having
consumed anything but water for the previous 12 hours. No more than 18 mL (3-4
teaspoons) of blood will be drawn from a forearm vein in a single blood draw, and no
more than three complete blood draws totaling no more than 54 mL (10-11 teaspoons)
of blood will be collected within a single laboratory visit. Of the total amount of
blood drawn, no more than 5 mL (approximately 1 teaspoon) will be stored frozen for
future research studies in the event that the analysis of additional CAD risk factors can
be completed with support from future research grants. After the initial blood draw, I
will be given a lime-flavored sugar solution to drink. My blood will be drawn again at
1 and 2 hour intervals after I finish drinking the sugar solution. The sugar solution
will stimulate insulin secretion from the pancreas (a digestive organ) and into the
blood. Greater amounts of blood insulin after drinking the sugar solution are
associated with a greater risk for heart attacks. Thus, the study will determine whether
participation in the three-month cardiac rehabilitation program effectively reduces
blood insulin levels after drinking a sugar solution. Although all of my blood for the
present study will be drawn at Good Samaritan Hospital, some of the blood will be
analyzed in the Clinical Laboratory at Good Samaritan Hospital, and some of the
blood will be stored frozen for later analysis in the Endocrine and Metabolism
Laboratory at Oregon State University.
CLINICAL EXAM AT OSU ENDOCRINE AND METABOLISM LABORATORY.
On the day of the clinical exam before and after the three-month cardiac rehabilitation
program, I will arrive at the OSU Endocrine and Metabolism Laboratory, and the
following will happen:
BODY MEASUREMENTS. I will wear light shorts and a short-sleeve shirt that can
be easily moved for the accurate measurement of body weight, height, girth, and
diameter measurements. My body weight will be measured on a beam scale. My
height and the length of my trunk from the neck to the hip will be measured with a
wall-mounted measuring stick. My abdominal fat will be measured by body girths
and an abdominal thickness measurement. My body girths will be measured with a
measuring tape at the waist, abdomen, hip and thigh. A special caliper will be used to
measure the thickness of my abdomen while I lie on an examination table. If! have a
heart pacemaker, I will not undergo the bioelectrical impedance testing.77
However, if I do not have a heart pacemaker, then the fat and non-fat composition of
my whole body and my trunk will be determined by a bioelectrical impedance
analyzer. The bioelectrical impedance analyzer will introduce a painless, low-voltage
(less voltage than that delivered by a small transistor radio battery) electrical current
into my body, so that the research staff can assess my body composition. Because
muscle is primarily composed of water and typically contains very little fat, muscle is
an excellent conductor of electricity, and it provides little impedance (or resistance) to
an electrical current. Fat tissue, by contrast, typically contains very little water. As a
result, body fat is a poor conductor of electricity, and it provides a lot of impedance
(or resistance) to an electrical current. Thus, by measuring the extent to which my
body and my trunk conduct or resist the electrical current, the research staff can
estimate the amount of fat and non-fat tissues contained in my body and in my trunk.
During the bioelectrical impedance measurement, I will lie on my back on a padded
examination table while a technician attaches small electrodes to the wrist, the ankle,
the neck, and the thigh on the right side of my body. The technician will then attach
electrical wires to: a.) my right wrist and ankle to assess my whole body impedance,
and b.) my neck and the upper part of my right thigh to assess my trunk impedance.
Once the electrical wires are attached to the electrodes, the technician will push a
button on the impedance analyzer which will introduce the low voltage current into
my body, and within only a few seconds of time, the impedance analyzer will assess
the extent to which my body conducts or resists the electrical current.
QUESTIONNAIRES. I will complete a medical history questionnaire, and I will
respond to questions posed during an interview with a member of the laboratory staff
about my physical activity over the past 7 days. I will also complete a questionnaire
related to my dietary habits, my use of vitamin and mineral supplements, and my
cigarette smoking behavior. Finally, I will complete two additional questionnaires
designed to assess different components of stress that I may or may not have. One
questionnaire focuses on assessing symptoms of depression, and the other
questionnaire focuses on assessing feelings of hostility. Although the stress
questionnaires focus on depression and hostility, I understand that neither
questionnaire may be used to diagnose depression or a hostile personality trait.
Furthermore, I understand that neither Dr. Williams nor any member of his research
staff is trained in psychology and therefore cannot or will not make any psychological
evaluations based on my responses. Instead, my responses to the stress questionnaires
will solely be interpreted relative to their known association with heart attacks or with
their possible association with the physical CAD risk factors assessed in the present
study. I understand that the questionnaires are detailed and that they include many
questions about my own and my family's health that may even seem burdensome or
intrusive. I understand that if I find any part or parts of the questionnaires to be overly
burdensome or intrusive, I am under no obligation to complete it, and that my decision
will in no way affect my participation in the other parts of the study.78
3-MONTH CARDIAC REHABILITATIVE INTERVENTION. I will be participating
in a supervised cardiac rehabilitation program that is managed bya nurse. The
program will be individualized and specific to my risk factors for heart disease. I will
be involved in an exercise program that will consist of both aerobic and low-level
weight training. Activities in which I can expect to participate include walkingon a
treadmill, using a rowing machine, riding a stationary bicycle, andsome moderate
weightliffing. In addition to the exercise program, there will be educational
opportunities designed to increase my personal knowledge aboutmy risks for heart
disease. These opportunities will include information related tomy diet, blood
pressure, and stress levels.
PRE- AND POST-INTERVENTION TESTING. I understand that I will be asked to
complete the sugar solution test at Good Samaritan Hospital and all of the clinical tests
to be conducted at the OSU Endocrine and Metabolism Lab twice- once before and
once again after participating in the three-month cardiac rehabilitation program at
Good Samaritan Hospital.
FORESEEABLE RISKS OR DISCOMFORTS. I understand that Imay experience
some discomfort while my blood is being drawn, and that this procedure could result
in a small amount of bleeding, bruising, and slight soreness at the site of the needle
insertion. I have been informed that my blood will be drawn by trained hospital
personnel who will apply a bandage to my arm to prevent bleedingor bruising as a
result of my blood being drawn.
I understand that I may experience some muscle and joint pain,soreness, and possible
injuries related to my participation in the exercise part of this study. I have been told
that my exercise program will be individualized to my abilities, and all attempts will
be made to gradually increase my exercise to reduce the potential for exercise-related
pain, soreness, and injury.
I understand that after drinking the sugar solution, there is a remote chance thatmy
blood sugar levels may drop to low levels, which could produce dizziness, headache,
and loss of consciousness. In the rare event of a low blood sugar reaction, appropriate
medical personnel at Good Samaritan will be available to monitor my condition and, if
necessary, correct my blood sugar deficiency. Furthermore, the possibility of
experiencing a low blood sugar reaction will be minimized by usinga dose of sugar
that is similar to the amount of sugar consumed in a typical meal.
I understand there exists the possibilities of some unfavorable changes during exercise
in the cardiac rehabilitation program. They include abnormal blood pressure, fainting,
disorders of the heart beat, and in rare instances, heart attack, stroke, and death.
Appropriate heart monitoring during exercise, supervision by an experienced cardiac
rehabilitation staff, and the close proximity of the emergency room during the exercise
classes at Good Samaritan Hospital will minimize the risks associated with regular
exercise in the cardiac rehabilitation program.79
I understand that there may be some psychological risks associated with completing
the stress questionnaires. For instance, I may observe that my responses are consistent
with possible symptoms of depression or with trends toward a hostile personality that I
have never before considered. Such new considerations may be painful or upsetting.
POTENTIAL BENEFITS. I understand that my regular participation in the cardiac
rehabilitation may reduce some of my risk factors for future heart attacks. I also
understand that the measurements of body fat around the abdomen, blood insulin
levels, blood cholesterol levels, physical activity, dietary intake, smoking behavior,
and stress levels, which will be sent to me at the end of the study, may be important to
me or my physician for assessing potential changes in my own personal risk for future
heart attacks. Furthermore, I understand that the information obtained in the present
study may help Dr. Williams and his associates learn how to better prevent excess
amounts of body fat around the abdomen and high levels of blood insulin after
drinking a sugar solution, which in turn, may lead to better prevention of heart attacks
in patients with CAD.
E. Confidentiality
I understand that any information obtained from me, including test results, will be kept
confidential. A code number will be used to identify any samples, test results, or other
information I might provide. The only persons who will have access to this
information will be the investigators.
F. Compensation for injury
I understand that Oregon State University does not provide research subjects with
compensation or medical treatment in the event that I become injured as a result of
participation in this research project. However, if! sustain any injury during the data
collection, trained personnel will provide first aid.
G.Voluntary Participation
I understand that my participation in the project is completely voluntary, and that I
may withdraw from or refuse to participate in the study at any time with no effects on
my participation in the cardiac rehabilitation program.
H.Questions regarding the study
I understand that any questions I have about the study or any specific procedures
should be directed to Daniel P. Williams, Ph.D. (principal investigator at Oregon State
University) at 737-5922 or to Kern Eason, R.N. (cardiac rehabilitation program
supervisor at Good Samaritan Hospital) at 757-5323. Any other questions that! have
should be directed to Mary Nunn, Sponsored Programs Officer, OSU Research Office
at 737-0670.80
I. Understanding and consent
My signature below indicates that I have read and that I understand the procedures
described above. I give my informed consent to participate in this study. I understand
that I will receive a signed copy of this consent form.
Signature of Subject Name of Subject
Date Signed
Subject's Present Address
Subject's Phone Number
Signature of Investigator Date Signed81
Appendix C: Screening Form
PATIENT SCREENING FORM
1. Name Screen ID
Last First Middle
Best time/place to contact?
2. Telephone
Home( )_____ ___________________________
Work( )__________________________________
3. Interviewer DateIITime :AM/PM
mo day yr
4. Whether eligible or not, would you be willing to be contacted in future for
other studies? (If yes, get address) Circle: 1=yes 2no
Mailing Address:
Street Apt. #
City State Zip Code
5. Definitive diagnosis of coronary artery disease 1=yes 2=no
Subjects responding affirmatively to anyof5a-5e are eligible with a definitive
diagnosisofCAD, whereas subjects answering negatively to allof5a-5e are ineligible
for the present study.
Why were you referred to cardiac rehabilitation?
a. recent coronary artery bypass surgery? yesno
b. recent heart attack? yesno
c. recent positive angiographic, ECU, or thallium test? yesno
d. recent angioplasty procedure? yesno
e. recent stent procedure? yesno
For all subjects with and without a definitive diagnosis CAD, please determine
whether items 5f-5k apply to their current medical condition or whether items 5f-5k
may explainwhy they were referred to cardiac rehabilitation.
f. recent heart valve replacement? yesno
g. recent diagnosis of cardiomyopathy? yesno
h. recent diagnosis of cardiac arrhythmia? yesno
i. recent cardiac transplant? yesno
j. recent diagnosis of non-CAD heart disease? yesno
k. recent multiple risk factor diagnosis? yesno82
6. Exclusion Criteria (continued)
Subjects responding affirmatively to 6a-6e are ineligible for the present study.
Medical History 1 = yes 2 = no
Has a physician ever told you that you have or had the following?
a. diabetes (both NIDDM and IDDM are exclusionary) yes no
b. any medical conditions that severely limit physical activity yes no
- severe orthopedic conditions yes no
- severe COPD yes no
- severe CHF yes no
- severe claudication pain yes no
Medication 1=yes2=no
c. Are you currently taking insulin (humulin, humalog,
novolin, velosulin, etc)? yes no
Personal Factors 1=yes2=no
d. Will you be moving away from the Corvallis area in the
next 3-6 months? yes no
e. Do you reside more than 50 miles away from Corvallis
and/or anticipate time or transportation constraints that may
limit your participation in activities promoted by the rehab
program and the four separate rounds of clinical tests in the
research study? yes no
f. Besides time and transportation constraints, do you have
any other personal considerations that may limit your
participation in activities promoted by the rehab program
and the four separate rounds of clinical tests in the research
study? yes no
7. Intervention Information (non-exclusionary information)
a. Is the subject at "high risk" for events or complications
resulting from participation in the cardiac rehab program
that will require that the participant undergoes a modified
rehab program? yes no
b. Comments regarding basis for and nature of modifications
required:Appendix D: Blood Draw Assessment Form
Blood Draw Assessment
Subject Name
Subject Number
Test Date (mmlddlyy)
Visit (A=pre-cardiac rehab; B=post-cardiac rehab)
Birthdate (mmlddlyy)
Age (years)
Race (O=Caucasian; lBlack; 2=flispanic; 3=Asian; 4=Other)
Technician Initials
/ /
I I
83
Time of Blood Draw (hour:min)
U U U U U UUU UU U UU U U U U U UUU U U UUU U U UUUUUUUUUU UU U UUU U U UUU U U U U UUI
A. Subject Preparation
1. When did you last eat a meal or a snack?
(date in mmlddlyy) (timeof day in hour:min)
2. What did you eat (try to determine approximate amounts of foods eaten)?
3. When did you last drink some fluids?
(date in mmldd/yy) (timeof day in hour:min)
4. What did you drink (try to determine approx. amounts of beverages
consumed)?
5. Have you taken any medications or nutritional supplements in the past 3 days?
(1=yes, 2=no)
Ifyes, please ask question #6. If no, then determine whether there areany
"typical" medications or supplements used, and continue with questionnaire.84
Blood Draw Assessment
Subject Name
Subject Number
Test Date (mmldd/yy) / I
Visit (A=pre-cardiac rehab; B=post-cardiac rehab)
Birthdate (mmlddlyy) / /
Age (years)
Race (O=Caucasian; l=Black; 2=Hispanic; 3=Asian; 4=Other)
Technician Initials
Time of Blood Draw (hour:min)
. . . ... . . . U UUU U U U U U U UUU U U . . .U U UUUU U UU U{
A. Subject Preparation (continued)
6. What specific medications or nutritional supplements did you take in the past 3
days?
Date Approx. Time Med or Supplement Dose
Ifany of the above includes hormone replacement therapy, then please continue with
questions on the following page.Ifnot, then please resume with question 10 on page
4.Blood Draw Assessment
Subject Name
Subject Number
Test Date (mmlddlyy)
Visit (A=pre-cardiac rehab; B=post-cardiac rehab)
Birthdate (mmldd/yy)
Age (years)
/ I
/ /
85
Race (O=Caucasian; 1=Black; 2=Hispanic; 3=Asian; 4=Other)
Technician Initials
Time of Blood Draw (hour:min)
I.UUUU. U UU U UU UUU U U U UUU U U U U U UUU U U U U U U U U U UU U U UU U U U U ..UU
A Subject Preparation (continued)
7. Which of the regimens below best describes your current hormone replacement
therapy?
a.estrogen-only for each day of the month.
b.estrogen-only for part of the month.
c.estrogen + progestin each day of the month.
d.estrogen + progestin for part of the month and stop taking both for the
remainder of the month.
e.estrogen for each day of the month and progestin for part of the month.
f.estrogen for most of the month, progestin for part of the month, and neither
for the remainder of th emonth.
g.other, please describe:
8. Which of the below best describes your current mode of hormone replacement
delivery?
a.oral (pills)
b.implant
c.topical creams
d.other, please descrive:
9. If you undergo a cyclic monthly oral hormone replacement regimen, please
define today as one exact day in your monthly regimen (i.e., day 10 of
estrogen-only).86
Blood Draw Assessment
Subject Name
Subject Number
Test Date (mmldd/yy) I /
Visit (A=pre-cardiac rehab; B=post-cardiac rehab)
Birthdate (mmldd/yy) / /
Age (years)
Race (0=Caucasian; 1=Black; 2=Hispanic; 3=Asian; 4=Other)
Technician Initials
Time of Blood Draw (hour:min)
. . S S S S S 55 SUUS U U U 55555 U.... . . . . ...u U U U U U 55CU S S S UI
A Subject Preparation (continued)
10 Do you exercise regularly? (1=yes; 2=no)
11.Did you exercise in the last 3 days ? (1=yes; 2=no)
12.When did you complete your last bout of exercise?
(date in mmldd/yy) (time of day in hour:min)
13.What type of exercise (or activity) did you do?
(mode)
14.For how long did you exercise? (total elapsed duration in mm)
15.Did you exercise without stopping, or did you repeatedly stop and start?
(1 =continuous; 2=intermittent)
16.How hard (intensity) did you exercise?
(1=less than brisk walking; 2=same as brisk walking; 3=greater than brisk
walking)
17.At what time did you get up this morning (time of day in hour:min)_________
18.At what time did the subject consume the oral glucose beverage?
1 -hour postload time of day 2-hour postload time of day
(estimated) (estimated)
(actual) (actual)87
Appendix E: Body Composition Data Collection Sheet
Cardiac Rehabilitative Effects on Insulin Resistance in Patients with Coronary Artery Disease
Body Composition Data Collection Sheet
Subject ID
Test Date (mm/dd/yy)
Visit (Abaseline; B=three month post-intervention)
Birth Date (mm/dd/yy)
Technician (initials)
I I
/ I
Recorder
1) Heights and Weight
Height (cm)
Weight (kg)
Trial 1 Trial 2 (two trials within <0.5 cm)
Leg Height (cm)
Sternal Notch Height (cm)
2) Circumferences (cm) -three trials within < 1.0 cm
Trial 1 Trial 2 Trial 3
Waist
Abdominal
Hip
Thigh
3) Sagittal Abdominal Diameter (cm) - three trials within < 0.5 cm
Trial 1 Trial 2 Trial 3
Sagittal Diameter
4) Bioclectrical Impedance (ohms) (most stable reading during first 10 sec)
Whole Body Resistance
Trunk ResistanceAppendix F: Attendance Record
Subject ID:
CR Start Date (indicated by first X):
Estimated 3-month finish:
Last CR:
Last Post -test Date (indicated by 0):
CALENDAR CR ATTENDANCE
(use as a visual aide to determine CR pattern, of the three rows, the first represents
calendar date, second to indicate "1" for CR attendance and "0" for no CR, third line
to indicate the day# within the total three months)
Cardiac Rehab Month ONE
I:2 : 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 1920 21
22 23 24 25 26 27 28
29 30 31
Cardiac Rehab Month TWO
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 1920 21
22 23 24 25 2627 28
29 30 31
Cardiac Rehab Month THREE
I 2 3:4 5 6 7
8 9
:10 11 12 13 14
15:16 17 18 19 20 21
2223 24 25 262728
29 30 31
Cardiac Rehab Month FOUR
1 2 3 4 5 6 7
8 9 110 II 112
:13 14
15 16 17 18 119 20
.1 -------------- .1-------21
L______
22 23 24 :2526 27 28
29 30 31
88Subject ID
Testdate
Visit (A=baseline; B=post-intervention)
Technian initials
/ / Endocrine and Metabolism Laboratory
Oregon State University
Department of Health and Human Performance
7-Day Physical Activity Recall
Day of the week form completed:
1.Were you employed in the last 7 days (work & volunteering)? Yes 2No
2. How many total days of the last 7 did you work outside the home? no. of days (round to nearest day)
3. How many total hours did you work in the last seven days? at work at homefltotal hours
4.What days of the week do you consider to be your weekend or non-work days? For most people this would be Saturday and
and Sunday but it may be different for you.
0Sunday 20 MondayEThesday0Wednesday0Thursday0Friday ,Saturday
5.If you did not work your usual week, why did you work less than usual?
6.For the past seven days, and thinking only about activities that are at least of moderate intensity
how many days did you do activity or exercise that added up to at least 30 minutes each day? 0number of days (0 to 7)
7-day recall explain nemen of day
am. wake-lunch
pm. lunch-dinner
evs.dlnner4leep
00One Week Ago Yesterday
I)wrk pd&olunu
Sleep.2) eleep week
eI.epweekeed
nape
3) w aid yea do
w4ewedyoago
wo
houukold
Moderate
pee
000
4)Sdy,
aapotkacdnnes
Hard
., .
0
VeryHard
Calculated Energy Expenditure kcallkglday PhysicJ Acthlty Recill - Page 2 of 7One Week Ago Yesterday
I)wod pd&v&uncr
Sleep
2) sleep week
sleep weekeed
3)wb.tdpoidø
wwêdyoeto
work
koosekold
lelsore
Moderate
pin
eve
4) load7,
other acOlvikes
0
0
Hard
.1
'I-
Very Hard
Calculated Energy Expenditure kcal/kg/day PhyolcJ ActMty Recall - Page 3 of 7 '0One Week Ago Yesterday
I)* pd&volornr
Sleep 2) Iew.-
npl
3)+.atdyodo
woc
household
Moderate
p.?'
ve
4) hdy,
Hard.
w
VeryHard
Calculated Energy Expenditure kcal/kg/day PhysiQl ActMty Reaji- Page 4 of 77. Was this a typical week in terms of your usual pattern of activity or exercise?
Yes
No Were you more or less active in the past week than you usually are? More Less
3-Month Physical Activity Recall
8.During your work week, on average how many hours per day do you spend sitting quietly?Eaverage hours per day
(e.g., watching TV, working at a desk or computer, eating, or reading) (consider all waking time - before work and after)
During your weekend, on average how many hours per day do you spend sitting quietly?E Eaverage hours per day
(e.g., watching TV, working at a desk or computer, eating, or reading) (consider all waking time - before work and after)
9. How many flights of stairs do you climb up each day? (1 flight = 10 steps) number of flights
10. If you had to add together the total minutes you spend walldng during the day, how many minutes
would that be? Remember, add up your actual walldng time and don't add in the time spent just standing.
Include your to and from walking and any fitness walking. Don't Iry to remember every step, just give a
general idea of the time spent walking. E E Etotal minutes per day
11. What is your usual pace of walking? Mark one only.
Casual or strolling (less than 2 miles per hour) ,Fairly brisk (3 to 4 miles per hour)
2EAverage or normal (2 to 3 miles per hour) 41 Brisk or striding (4 miles per hour or faster)
12. Do you regularly do strength and flexibility exercises like sit-ups, push-ups, yoga, or stretching?
Yes How many days per week do you do these exercises?number of days (0-7)E E Etotal minutes ea session
EliNo
Physlcsl Acdvty Recill - Page 5 o(7Interviewer Evaluation
1. Were there any problems with this survey?
Yes No Explain
2. Do you think this was a valid interview?
Yes No Explain
3. List any activities reported by participant which you don't know how to classify
FORII compteted by (Inths) a baeUne PiysicaI Activity R.c- Ptge 7 of 7Appendix H: Food Questionnaire
This form asks about your usual food intake
over the past year. It takes about 30 minutes
to complete. Please follow these instructions:
Answer each question as best you can -
estimateyou aren't sure.
Use only a #2, ordinary pencil.
Be certain b completely blacken in each of
your answers, and erase completely if you
make any changes.
Do not make any other marks on this form.
lfyouwishtomakecomments,pleaseusea
separate piece of paper.
I- -1
'HI"
l) 4)4) 4)4)4)4)'
4) 44 4) 4)1
*4 *4 4) 4) 4) 4)
4) *4 4) 4) 4) Ii
C) C) C) C) C) C)
'') 4) 4) I) II
44) 4, 4 I 4 4 4 4 C I
là49II .i *1
p44
) 4) 4) 4) 4) 4) 4)!
-
I
11 LAST NAME 25 FIRST MI
LII IIIIWIHHIIHI :
35 STREEr ADORESS
HHIHHIHIHIm
59 cay 73 STATE -
76 ZIPCODE -
iii
96ii
PI4ONENO.ni
-
SOCIAL SECURITY
NUMBER
4 4.) 4) 4) 4) 4) 4) 4) 4
4) 4) 4) 4* 4) 4) 4) 4I
4) 4) 4) 4) 4) 4) 4) 4) 4I
44) 4) 4) 4) 4) 4) 4) 4)
cC) C) C) C) C)
444
4)4)4)4) C) 4)4)
...., .
) C) 4) 4) 4) 4) 4) 4) I 44
4) 4) 4) 4) 4) 4) 4) 4) 4)!
SEXoMaleoFemale
If female, are you
pregnant or
breast feeding?
O No
O Yes
oNot female
HHHO.BLOCK.95Phone or far (510) 704-8514
AGE
I') 'I
I"I
1 1" ' I
49
C.,
là là
(5 (4
4) 4)
WEIGHT
pounds
C,) (.)
4) 41 4)
4) 4-)
4') 4')
C)4)C)
4 43
(3 4)
SI I
o6)
4) 4)
HEIGHT
ft. in.
as
PLEASE DO NOT WRITE IN THIS AREA UIOOUNIMUOOO0000000 24478
a
Prinind In U.S.A. Mark Refle,8 by NCS MM103594.2 32
N N _ N N-
95During the past year have you taken any vitamins or minerals regularly (at least once a week)?
ONo Yes, fairly regularly TYes, but not regularly
IF YES, WHAT DO YOU TAKE FAIRLY REGULARLY?
96
VITAMIN TYPE HOWrm
OFTEN FORHOWMANYYEARS?
DAYSDAYS LESS
DON'rPERPERVERY THAN 1 2 3-4 5-910+
TAKEWEEKWEEKDAY 1 YR.YEARIARSEARS AS $
Multiple Vitamins
Regular Once-A-Day, Centrum, or Thera type0000 000000
Antioxidant combination type 0000 000000
Single Vitamins (not part of multiple vitamins)
Vitamin A (not beta-carotene) 0000 000000
Beta-carotene 0000 000000
Vitamin C 0000 000000
VitaminE 0000 000000
Calcium orTums 0000 000000
Iron 0000 000000
Zinc 0000000000
Selenium 0000 000000
if you take multiple vitamins
Do you usually take types that0contain minerals (iron, zinc, etc.)0do not contain minerals0Don't know a
If you take Vitamin C or Vitamin E:
How many milligrams of vitamin C do you usually take, on the days you take it?
010002500500075001000015000200003000+ a
How many lUs of vitamin Edo you usually take, on the days you take It?
0100020003000400060008000100002000+
The next section is about your usual eating habits over the past year.
= FIRST:Mark the column to show HOW OFTEN, on the average, you ate the food during the past year.
SECOND: Mark the column to show HOW MUCH you usually eat of each food.
"Sometimes the "how much" is asked as number of pieces, such as 1 egg, 2 eggs or 3 eggs.
Mark your serving size as the number you usually eat ON THE DAYS YOU EAT IT.
Sometimes the "how much" is asked as small-medium-large (S-M-L).
A medium" portion is shown for each food, but only as a guideline. The medium" portion that will actually
be used In the calculations Is larger for men than for women, and larger for young people than for older
people. Mark smalr If you think you usually eat a smaller portion of that food than other people of your
age and sex. Mark "large" If you eat moreofit than other peopleofyour age and sex. a
SAMPLE: This person eats one orange about twice a week, and eats a medium serving of other fruit about
three times a week.
a
HOW OFTEN
1 2-3 1 2 -11
110W MUCH a - -
YOuR SERVING SIZE LESS ThAN PERPERPERPER PERPERVER
MEDIUM TYPE OF FOOD ONCE PER
uopimMON. MON. WEEK WEEK WEEK WEEK DAY I I S U IL
1 I2
Oranges 00 0 00 0 0 1 medium 0 0
a
Other fruit 00 0 0 0 S 0 0 112 cup0 I0 _______ __ __sIuL
DO NOT WRITE IN THIS SHADED AREA
a - - 2"PLEASE DO NOT WRITE IN THIS AREi.
HOW OFTEN HOW MUCH
NEVER YOUR
TYPE OF FOOD oii LEss
124 1 2 3-45-6 1 SERVING SIZE
PER PER PER PER 1PER PER EVERY' MEDIUM THANONCE
MON. MON. WEEKNEEKWEEK WEEK, DAYSERVING puo.im s M
EXAMPLE: Bananas 00C)S0 0 OIL)1 medIum050 _______________
Bananas 0000 CDCCC__
I medium
--
0
-
00
112 I 2
Apples, applesauce 00000C001 medium000
112 1 2
Oranges (not including juice) 00000C001 medium000
. 1 2
Grapefruit (not including juice) 0000000
I0 ium000
114 112 1
Cantaloupe I00000C00
1/4
medium000
Ill 114 112
Peaches, apricots (fresh, in season) 00000C001 medium000
112 1 2
Peaches, apricots (canned or dried) 00000C00
1 medIum
or 1/2 cup000
S M I.
Prunes, or prune juice 00000000 1/2 cup000
S N L
Watermelon (in season) 00000000 1 slice000
S U L
Strawbenies, other berries (in season)00000000 1/2000
S U L
Any other fruit, including kiwi, fruit 00000000 1/2 cup000 cocktail, grapes, raisins, mangoes S U L iiiii'i _________
Fiber cereals like raisin bran,__
00000000__
1 medium000 granola or shredded wheat bowl
Sweetened cereals like frosted 00000000
imedium000 flakes S N L
Other cold cereals like corn 00000000
1 medium000 flakes orcheerios S U I.
Cooked cereal like oatmeal, oat 00000000
imedium000
branorgrits $
Milk on cereal 00000000 1/2cup000
S U L
Breakfast bais, granola bars, 00000000iserving000
power bars s u I.
Breakfast shakes, diet shakes 000000001 servIng000
UI
Pancakes or waffles 00000000 2 med.000
I S $
Eggs 000000C)C)I egg=sml.
2eggs=med.GD(2)(2)
aceeggseggs
Egg substitutes. Egg Beaters, egg whites00000000 2 eggs CD(2)(2)
egg.ggssggs
Sausage or bacon 000000002pattiesor
GD (2)
Cottage cheese 0000C0C0 1/2 cup000
$ UI
Other cheeses and cheese spreads 000000002 slices or000 (regular or lowfat) 2ounces I 2
Yogurt, frozen yogurt (regular or lowfat)00000000 a
contaIner000
5... 1005.
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HOW OFTEN HOW MUCH
NEVER
1 3
MEDIUM
1
YOUR
SERVING SIZE ORLESS
PERPERIPERIPERIPERPER kVERY THAN ONCE
tON MON. WEEKIWEEK WEEK PER MONTH fWEEK{ DAYSERVING jS M L
VEGETABLES (fresh, frozen or canned, or In restaurants)
String beans, green beans 00000000 1/2 cup000
Peas 00000000 l/2cup000
Chili with beans (with or without meat)00000000 1 cup000
Other beans such as baked beans,
pintos, kidney (not including soup) 00000000 3/4 cup000
Corn 00000000 1/2cup000
Alfalfa sprouts, including on
sandwiches 00000000 1/2cup000
Tomatoes, tomato juice 00000000I medium or
6g000
Salsa, ketchup, taco sauce 000000002 tablesp.000
Broccoli 00000000 1/2 cup000
Cauliflower or brussels sprouts 00000000 1/2 cup000
Spinach (cooked or raw) 00000000 1/2 cup000
Mustard greens, turnip greens, 00000000 1/2 cup000 collards
Cole slaw, cabbage 00000000 1/2 cup000
Carrots, or mixed vegetables
containing carrots 00000000 1/2cup000
Green salad 00000000I medium000
Salad dressing&mayonnaise
(regular or Iowfat) 000 00002 tablesp.000
French files and fried potatoes 00000000 3/4 cup000
White potatoes not fried, including boiled,000000001 medium000 baked, mashed and in potatosalad orl/2cup
Sweet potatoes, yams 00000000 1/2 cup000
Any other Vegetable, such as
cooked onions, summer squash 00000000 I/2cup000
Butter, margarine or other fat
added to veg., potatoes, etc. 00000000 2 pats000
Tofu, beancurd 00000000 1/2cup000
Meat substitutes made from soy 00000000 I cup
or patty000
NEVER
ORLESS
I
2-3 1 234
ThAN ONCE PERLr
PER R
EER I PERMONTH11M41 EK EK1EKEK DAY
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244780000000000UUUUUUccUUUUL
HOW OFTEN WMUç!i
NEVER I YO'JRl
TYPE OF FOOD ORLESS 1I 24 1 2 3-45-6
ThAN oNCE PER PER PER[PERPER PERVERY1MEDIUMSERVING SE
PER MONTh MON.] MON.EEKNEEK1NEEK?EEK DAYSERVINGML
MEATS, SOUPS, PASTA
Hamburgers, cheeseburgers 00000000
fl1Ufl1000 o4oz.
Burrftos or tacos with meat or beans 00000000 medium000 or 2 small
Beef roasts, steaks, sandwiches 000000004 ounces,000
Uver, including chicken livers 000000004ounces000
Pork, including chops, rOasts 000000002 chops or
4 ounces000
Friedchicken 000000002smallor
I large pce.000
Chicken or turkey (roasted or 000000002 small or000 broiled, including on sandwiches) I large pce.
Chicken stew or mixed dish with
thicken 00000000 icup000
Fried fish or fish sandwich 000000004 ounces or
1 saedwicti000
Tuna, tuna salad, tuna casserole 00000000 1/2 cup000
Oysters 00000000
5 pieces,
1/4cup000
or 3 oz.
Shell fish, (shrimp, crab. 5 pieces,
lobster, etc.) 00000000 1/4 cup000
0r3 oz.
Other fish (broiled or baked) 000000002 pieces or
4 ounces000
Beef or vegetable stew or pot pie with
carrotsandothervegetables 00000000 icup000
Spaghetti, lasagna, other pasta 00000000 000 wIth tomato sauce
Cheese dishes without tomato sauce,
like macaroni and cheese 00000000 Icup000
Pasta salad, otherpasta without
tomato sauce 000000003/4cup000
Pizza 000000002shcesCD®(I)
lacelaceslaces
Hot dogs 000000002hotdogs )CD CD
dogdogsdogs
Ham, bologna, other lunch meats 000000002 slicesor (2) Cli) (regularormade wtth turkey) 2ounces.aciScesSliCeS
Vegetable soups with carrots or tomatoes,00000000lflledIUm000 such as vegetable beef or tomato soup $ U L
Lentil, pea and bean soups 00000000rneum000
5 U L
Other soups, like chicken noodle, 00000000I medium000 mushroom, cup-a-soup, ramen N
INEVER 24 1 23454 ORLESS
ONCE PER PER
IER PER PERIPER EVERYI
HMom1 MON.ONJWEEKrEEKEEK#JEEKjj
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HOW OFTEN HOW MUCH
TYPE OF FOOD
NEVER 1
MEDIUM
YOUR
ThAN ONCE PER PER PER PER PER PER EVERY PER
PER MONTh MON. MON. WEEK WEEK WEEK WEEK DAYDAYSERVING S jM LXL
BREADS, SNACKS, SPREADS (Please note that the categories for these columns are different.)
Biscuits muffins 1 medium0C0 (including fast foods) -- pi
Bagels,Enghshrnuffins, H000lmeum o-
White bread, French or Italian - U slices
bread,includingsandwiches 0 0 0eSChtI,fle
,£
Dark bread, such as whole #slices
wheat, rye, pumpernickel 000 0 0esch time
Corn bread, corn muffins -o-::o o 0
U pieces
each time Q) pepieces_
.Q)
Tortillas 0 C 00 0:010O..WCt) CA)
tort.2tort.3tort4to,t
Snacks like nachos with cheese, -. 1 medium
potato skins with topping 0 0 0 J0 0 seMng C)CC0
Saftysnackskepotatocps,
, 0000002hanthS o
Peanuts, peanut butter 00C 00 0 0002 tablesp.000
Margarine on bread or rolls 000 00 0000 2 pats C)00
Butter on bread or rolls 000 00 0000 2 pats000
Rice. or dishes made with uice00000 0000 3/4 cup0000
SWEETS
Ice cream (regular or lowf at)
Doughnuts, pastry
Cookies or cake (regular or
lowf at)
PumpkIn pie, sweet potato pie
Other pies
Chocolate candy, candy bars
Other candy or jelly
S N L XL
1/ ll 1!
MON. WEE DAY
0
000000000 Iplece0000
S N L XL
0000000000000
0000000001meUmo
000000000ImediUm
?
tD
000000000 Co0
000000000'999
N 6.N NHOW OFTEN HOW MUCH
NEVER OR YOUR
TYPE OF FOOD LESS ThAN 14 1 2-45-6 124
MEDIUM SERVING SIZE PER PER PER PER PER PER PERI ONCE PER
MONTHMON WEEK WEEK WEEK DAY DAY DAY DAY I!!NG
BEVERAGES (Please notethat the categories for these columns are
0 C)
different.)
Orange juice or grapefruit juice 6 oz. glass00C)
4o. I... I...
Applejuice,grapejuice 00 00 C CC) 6oz.glass000
4o.So.. so..
Whole milk (or Chocolate whole
milk), not including on cereal C) C) 0 8 oz. glass000
2% milk (or chocolate 2% milk),
C)0 0 8 oz.0
..
00 not including on cereal glass
500_ S lOo..
Skim milk, 1% milk, not including
on cereal C) C) 8 oz. glassC)C)0
Kool-Aid, Hi-C, or other drinks with
5 ,
added vitamin C 00C)C)C)C)C) 0 8óiglass000
Snapple, Calistoga, sweetened
o.. iso..
bottled waters or iced teas C) 0 C)C)C)C)0 1 bottle0
so..0
is...0
1500.
Regular soft drinks (not diet soda) ° 0C)12 oz.
or bottle00
12
Beer C)C)C)C) l2oz.canooo ortottie
Wine or wine coolers 0 C)C)C)0 C)C) 0 01 medium000
S N I
Liquor C) C)C)0C) C)C) 1 shot00
Coffee ortea 00 0C)0 0 0 0 01 medium000
$ N I
Non-dairy creamer
, C)0C)0 0 01 tablesp.000 incoffeeortea s I
Cream (real) or Half-and-Half inoo o o o o o o o itai,iesp.ooo coffee or tea N I.
Milk in coffee ortea 00 0 0 0 C) 0 0 C)llablesp.000
S U L
Sugaror honey in coffee o o 0 0 0 02teaspoons000 or tea or on cereal uj
About how often do you eat the followIng foods from restaurants or carry-outs?
Remember to think about all meals (breakfast, lunch, dinner or snacks).
NUMBEROF VISITSLAST YEAR
NEVER 1-4 5-11 14 ONCE 2-4 ALMOST RESTAURANT FOOD
IN PAST TIMES TIMES TIMES A TIMES EVERY
YEARPAST YEARPAST YEARA MONTh WEEK A WEEK DAY
0 0 00 00 0 Fried chicken
Burgers 0 0 0 0 0 0 0
Pizza 0 C) 0 0 0 0 C)
Chinese food, Thai or other Asian food0 0 0 0 0 0 0
Mexicanfood 0 0 0 0 0 0 0
Fried fish 0 0 0 0 0 0 0
DO NOT WRITE IN THIS SHADED AREA
- - .7.- _ _
101
a
a
a
a
a
a
a
a
a
a
a102
AVERAGE USE LAST YEAR
= SUMMARY QUESTIONS
PER R PER PER PER PER PER PER
WEEKWEEKWEEKWEEK DAY DAY DAY DAY DAY
a. How often do you use fat or oil
= b. About how many servings of
vegetables do you eat, not - oo counting salad or potatoes? U
c. About how many servings of fruit
do you eat, not counting juices? oooooooo
d. About how many servings of
cold cereal do you eat? o CD000000
e. About how many glasses of milk (or
chocolate milk) do you drink? 0 C)0 CD0000
What kinds of fat do you usually use in cooking (to fry or stir-fry)? Mark the one or two you
use most often.
0 Don't know Pam or no oil 0 Lard, fatback, baconfat 0 Cnsco shortening
0 Stick margarine Soft tub margarine 0 Low calorie margarine
0 Butter C Olive oil or canola oil0 Corn oil, vegetable oil
What kinds of fat do you usually add to vegetables, potatoes, etc.? Mark the one or two you use
most often.
0 Don't add fat 0 Lard, fatback, baconfat 0 Cnsco shortening
0 Stick margarine Soft tub margarine 0 Low calorie margarine
0 Butter C Whipped butter 0 Olive oil
When you eat the following foods, how often do you eat a low-fat or non-fat version of that food?
Cheese 0 Always low-fat CD Sometimes 0 Rarely low-fat
Ice cream or yogurt 0 Always low-fat 0 Sometimes 0 Rarely low-fat
Salad dressing 0 Always low-fat 0 Sometimes 0 Rarely low-fat
Cake or cookies 0 Always low-fat 0 Sometimes 0 Rarely low-fat
When you drink orange juice, how often do you drink a calcium-fortified brand?
0 Usually 0 Sometimes 0 Rarely
How often do you add salt to your food? 0 Seldom 0 Sometimes 0 Often
How often do you eat the skin on chicken? 0 Seldom 0 Sometimes 0 Often
How often do you eat the fat on meat? 0 Seldom 0 Sometimes 0 Often
How do you like your meat cooked? 0 Rare 0 Medium 0 Well done
Do you smoke cigarettes now?
ONo
0 Yes IF YES, on the average, about how many cigarettes a day do you smoke now?
01-506-14015-24 025-34 O35ormore
About how many times have you gone on a diet to lose weight?
ONever01-203-5 06-8 09-11Ol2ormore
is your health
0 Excellent0 Very Good 0 Good 0 Fair0 Poor
What language do you usually speak at home?
0 English 0 Spanish 0 Something else
Are you
0 Hispanic 0 White, not Hispanic 0 African American 0 Asian. Pacific Islander, Native American
THANK YOU VERY MUCH FOR TAKING THE TIME TO FILL OUT THIS QUESTIONNAIRE
Please take a moment to fill In any questions you may have skipped.
PLEASE DO NOT WRITE IN THIS AREA : UUmRooUUU...oR000000000 24478
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Appendix I: The Center for Epidemiologic Studies Questionnaire
Endocrine and Metabolism Laboratory
Oregon State University
College of Health and Human Performance
THE CENTER FOR EPIDEMIOLOGIC STUDIES QUESTIONNAIRE
Number:
Test Date: (mmldd/yy)__________________
Birth Date: (mmldd/yy)______________
Visit (A=baseline; B=post-intervention)
Instructions for Questions: Below is a list of the ways you might have felt or behaved in the past week.
Please respond by circling the most appropriate description of how frequently you may have felt this way
during the past week. Please do not write in the space marked "for investigator only".
For
Investigator During the Past Week
only
I was bothered by things that usually don't bother me.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
2. I did not feel like eating; my appetite was poor.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
3. I felt that I could not shake off the blues even with help from
my family or friends.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
4. I felt that I was just as good as other people.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)104
Instructions for Questions: Below is a list of the ways you might have felt or behaved in the past week.
Please respond by circling the most appropriate description of how frequently you may have felt this way
during the past week. Please do not write in the space marked "for investigator only'.
For
Investigator During the Past Week
only
5. 1 had trouble keeping my mind on what I was doing.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
6. I felt depressed.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
7. I felt that everything I did was an effort.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
8. I felt hopeful about the future.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
9. I thought my life had been a failure.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
10.I felt fearful.
a. Rarely or None of the Time (less than I day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
1!.My sleep was restless.
a. Rarely or None of the Time (less than I day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)105
Instructions for Questions: Below is a list of the ways you might have felt or behaved in the past week.
Please respond by circling the most appropriate description of how frequently you may have felt this way
during the past week. Please do not write in the space marked "for investigator only".
For
Investigator During the Past Week
only
12.Iwas happy.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
13.I talked less than usual.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
14.I felt lonely.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
15.People were unfriendly.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
16.I enjoyed life.
a. Rarely or None of the Time (less than I day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
17.I had crying spells.
a. Rarely or None of the Time (less than I day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)106
Instructions for Questions: Below is a list of the ways you might have felt or behaved in the past week.
Please respond by circling the most appropriate description of how frequently you may have felt this way
during the past week. Please do not write in the space marked "for investigator only".
For
Investigator During the Past Week
only
18.Ifelt sad.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
19.I felt that people dislike me.
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
20.I could not get "going."
a. Rarely or None of the Time (less than 1 day)
b. Some or a Little of the Time (1-2 days)
c. Occasionally or a Moderate Amount of Time (3-4 days)
d. Most or All of the Time (5-7 days)
TOTAL107
Appendix J: Medical History Questionnaire
MEDICAL HISTORY QUESTIONNAIRE
Subject Number
Test Date (rnmlddlyy)
Birth Date (mm!ddlyy)
Visit
(A=pre-cardiac rehab intervention; B=post-cardiac rehab intervention)
Instructions: Please mark an "x" in the space to the left of the most appropriate
response. Please choose only the most appropriate single response for each question.
1. What is your gender?
1. Female
2. Male
2. What is your current marital status?
1. Now married
2. Widowed
3. Divorced
4. Separated
5. Never married
3. What is your current employment status @lease mark only the best response)?
1. Employed and working
2. Employed and on a leave of absence
3. Performing volunteer work
4. Homemaker
5. Unemployed
6. Retired
4. What is the highest level of formal education that you have completed?
1. Attended school but did not complete high school
2. Completed high school
3. Attended but did not complete college bachelor's degree
4. Completed college bachelor's degree
5. Attended graduate school but did not complete graduate degree
6. Completed master's degree
7. Completed doctoral degree108
5 In which group do you consider yourself?
1. Caucasian
2. Asian, Asian-American, Pacific Islander
3. African-American
4. Hispanic
5. Native American, American-Indian
6. Other, please describe:_________________
6. How much was your household's total income for the past year?
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
00.
under $5,000
$5,000 to $9,999
$10,000 to $14,999
$15,000 to $19,999
$20,000 to $24,999
$25,000 to $29,999
$30,000 to $34,999
$35,000 to $39,999
$40,000 to $44,999
$45,000 to $49,999
$50,000 to $99,999
$100,000 and over
don't know
7. Which is the best description of your cigarette smoking habits?
1. never smoked regularly (skip to question 9)
2. former smoker (skip to question 9)
3. current smoker
8. How many cigarettes do you smoke on average per day?
1. ito 9 cigarettes
2. i0to 19 cigarettes
3. 20 or more cigarettes
9. What is thebest description of your alcohol consumption habits?
1. never drank alcohol (skip to question 11)
2. quit drinking alcohol (skip to question 11)
3. currently drink alcohol
10.How many alcoholic drinks do you consume on average per day (ldrink=12 oz
of beer, 4 oz of wine, or 1 shot of hard liquor)?
1. less than or equal to 1 drink
2. 2 drinks
3. 3 drinks
4. 4 drinks
5. 5 or more drinks109
11.What is the best description of your caffeinated beverage consumption habits?
1. never drank caffeinated beverages (skip to question 13)
2. quit drinking caffeinated beverages (skip to question 13)
3. currently drink caffeinated beverages
12.How many cups of caffeinated beverage do you consume on average per day?
1. less than or equal to 1 cup
2. 2 cups
3. 3 cups
4. 4 cups
5. 5 or more cups
13.Has your mother ever had a heart attack?
1. yes
2. no
3. don't know
14.Has your father ever had a heart attack?
1. yes
2. no
3. don't know
15.Have any of your siblings ever had a heart attack?
1. yes
2. no
3. don't know
16.Have either of your maternal grandparents ever had a heart attack?
1. yes
2. no
3. don't know
17.Have either of your paternal grandparents ever had a heart attack?
1. yes
2. no
3. don't know
18.Has your mother ever had diabetes?
1. yes
2. no
3. don't know
19.Has your father ever had diabetes?
1. yes
2. no
3. don't know110
20.Have any of your siblings ever had diabetes?
1. yes
2. no
3. don't know
21.Have either of your maternal grandparents ever had diabetes?
1. yes
2. no
3. don't know
22.Have either of your paternal grandparents ever had diabetes?
1. yes
2. no
3. don't know
23.Thinking back over the past year, about how many times did you see a
physician for medical attention (count office and hospital visits only)?
Number of visits: (please write in approximate number)
24.Has a physician ever told you that you have had a heart attack or a myocardial
infarction?
1. yes
2. no
3. don't know
25.How many heart attacks or myocardial infarctions have you had?
1. 0
2. 1
3. 2
4. 3
5. more than 3
6. don't know
Ifyour answer to question 25 is "0", please skip to question 29.
26.On what date did you experience yourfirst heart attack or myocardial
infarction?
Month (i.e., "January" is "01")
Day
Year
27.On what date did you experience your most recent heart attack or myocardial
infarction?
Month (i.e., "January" is "01")
Year111
28.Was your original heart aftack the first time that a physician had informed you
that you had coronary artery disease?
1. yes
2. no
3. don't know
29.On what date did a physicianfIrst inform you that you had coronary artery
disease?
Month (i.e., "January" is "01")
Day
Year
30.How many surgical treatments have you received for your coronary artery
disease? (A surgical treatment includes a coronary artery bypass operation, a
balloon angioplasty procedure, a stent procedure, or an atherectomy procedure)
1. 0
2. 1
3. 2
4. 3
5. more than 3
6. don't know
31.Which of the below best describes your most recent treatment for coronary
artery disease?
1. single vessel bypass
2. multiple vessel bypass
3. balloon angioplasty procedure
4. stent
5. combination of surgical procedures
6. no surgical treatments
32.On what date were you originally surgically treated for coronary artery
disease? (A surgical treatment includes a coronary artery bypass operation, a
balloon angioplasty procedure, a stent procedure, or an atherectomy procedure)
Month (i.e., "January" is "01")
Day
Year
33.On what date were you mostrecentlysurgically treated for coronary artery
disease?
Month (i.e., "January" is "01")
Day
Year112
34.Has a physician ever told you that you have had a stroke or a transient
ischemic attack (a "TIA")?
1. yes
2. no
3. don't know
35.Has a physician ever told you that you have peripheral vascular disease?
1. yes
2. no
3. don't know
36.Has a physician ever told you that you have congestive heart failure?
1. yes
2. no
3. don't know
37.Has a physician ever told you that have diabetes?
1. yes
2. no
3. don't know
38.Has a health professional (physician, nurse, etc.) ever told you that have high
blood pressure?
1. yes
2. no
3. don't know
39.Has a health professional (physician, nurse, etc.) ever told you that have high
blood cholesterol levels?
1. yes
2. no
3. don't know
40.Has a physician ever told you that you have cancer?
1. yes
2. no
3. don't know
41.Are you currently undergoing treatment for cancer?
1. yes
2. no
42.Has a physician ever told you that you have pneumonia?
1. yes
2. no
3. don't know113
43.Has a physician ever told you that you have gout?
1. yes
2. no
3. don't know
44.Has a physician ever told you that you have liver trouble or hepatitis?
1. yes
2. no
3. don't know
45.Has a physician ever told you that you have inflammatory bowel disease or
diverticulitis?
1. yes
2. no
3. don't know
46.Has a physician ever told you that you have gall bladder trouble or stones?
1. yes
2. no
3. don't know
47.Has a physician ever treated you for a duodenal or gastric ulcer?
1. yes
2. no
3. don't know
48.Has a physician ever told you that you have had a parasitic infection?
1. yes
2. no
3. don't know
49.Do you frequently get upper respiratory infections?
1. yes
2. no
50.Has a physician ever told you that you have had a urinary tract infection?
1. yes
2. no
3. don't know
51.Has a physician ever told you that you have rheumatoid arthritis or lupus?
1. yes
2. no
3. don't know114
52.Has a physician ever told you that you have asthma?
1. yes
2. no
3. don't know
53.Has a physician ever told you that you have emphysema?
1. yes
2. no
3. don't know
Questions 54-5 7 are for females only (for males, please skip to question 58).
54.Have you stopped having menstrual periods?
1. yes
2. no (skip to question 57)
55.At what age did you stop having menstrual periods?
Age: (please write in the exact or approximate age in years)
56.Why didyc
1.
2.
3.
4.
5.
u stop having menstrual periods?
reached menopause
had uterus surgically removed
had ovaries or ovaries and uterus surgically removed
uncertain
other reason, please describe:
57.Which of the below best describes your hormone replacement therapy history?
1. have never taken hormone replacement therapy
2. took hormone replacement therapy during menopause only
3. took hormone replacement for less than one year after menstrual
periods stopped
4. have taken hormone replacement therapy ever since menstrual
periods stopped
5. other, please describe:
58.Do you currently take any medication for chest pain (called "nitrate" or
"nitroglycerin" medications)?
1. currently take nitroglycerin
-common names include: Deponit NTG, Nitro-Bid, Nitro-Dur,
Nitrilingual, Nitrostat, Transderm-Nitro.
2. currently take other nitrates
-common names include: Dilatrate SR, Imdur, Ismo, Isordil,
Monoket, Sorbitrate.
3. currently take another type or a combination of medications for
chest pain, if so please list name of medication(s):
4. do not currently take any medication for chest pain.115
59.Do you currently take any medication to improve the pumping effectiveness of
your heart (called "inotropic" medications)?
1. currently take digitalis
-common names include: Cristodigin, Lanoxicaps, Lanoxin.
2. currently take other inotropic medications
-common names include: Dobutrex, Inocor, Primacor.
3. currently take another type or a combination of medications for
improving the pumping effectiveness of my heart, if so please
list name of medication(s):
4. do not currently take any digitalis or other inotropic
medications.
60.Do you currently take any medication to improve the stability of your heart
rhythm (called "antiarrhythmia" medications)?
1. currently take a group I antiarrhythmia medication
-common names include: Cardioquin, Ethmozine, Mexitil,
Norpace, Procanbid, Quinaglute, Quinidex, Rhythmol,
Tambocor, Tonocard.
2. currently take a group II antiarrhythmia medication
-common names include: Brevibloc, Inderal, Sectral.
3. currently take a group III antiarrhytbmia medication
-common names include: Betapace, Cordarone, Corvert.
4. currently take a group IV antiarrhythmia medication
-common names include: Calan, Cardizem, Isoptin.
5. currently take a miscellaneous group of antiarrhythmia
medication-common names include: Adenocard, Lanoxicaps,
Lanoxin.
6. currently take another type or a combination of medications for
improving the stability of my heart rhythm, if so please list
name of medication(s):
7. do not currently take any antiarrhythmia medications.
61.Do you currently take any medication to reduce the risk for blood platelet
aggregation (called "antiplatelet" medications)?
1. currently take aspirin or "ASA"
-common names include: Bayer, Bufferin, Ecotrin, Halfprin.
2. currently take other antiplatelet medications
-common names include: Flolan, Persantine, Reopro, Ticlid.
3. currently take another type or a combination of medications for
reducing the risk for blood platelet aggregation, if so please list
name of medication(s):
4. do not currently take aspirin or other antiplatelet medications.116
62.Do you currently take any medication to reduce the risk for blood coagulation
(called "anticoagulent" medications)?
1. currently take coumadin (also called warfarin sodium)
2. currently take heparin
-common names include: Fragmin, Heparin Sodium, Lovenox.
3. currently take another type or a combination of medications for
reducing the risk for blood coagulation, if so please list name of
medication(s):________________________________________
4. do not currently take coumadin or other anticoagulent
medications.
Questions 63 and 64 are for females only (for males, please skip to question 65)
63.Do you currently take hormone replacement therapy (called "estrogen,
progestin" medications)?
1. currently take conjugated estrogens only
-common name: Premarin.
2. currently take estrogen sulfates only
-common names include: Estropipate, Estrogen Sulfate, Ogen,
Ortho-Est.
3. currently take a plant estrogen only
-common name: Phyto-estrogen.
4. currently take premarin + a progestin
-common progestin names include: Cycrin,
Medroxyprogesterone Acetate, Pro gestin, Provera.
-common premarin + progestin combination names include:
Premphase, Prempro.
5. currently take any non-premarin estrogen + any progestin
6. currently take another type or a combination of hormone
replacement therapies, if so please list name of
medication(s):___________________________________
7. do not currently take any hormone replacement therapy.
64.Do you currently take a selective estrogen receptor modulator (called "SERM"
medications)?
1. currently take a SERM
-common name: Raloxfene.
2. do not currently take any SERMs.
65.Do you currently take any medication to lower your blood pressure (called
"antihypertensive" medications)?
1. currently take a diuretic (a water pill)
-common names include: Diazide, Enduron,
Hydrochiorothiazide, Triamterene.
2. currently take an ACE inhibitor
-common names include: Accupril, Altace, Capotil, Lotensin,
Mavik, Monopril, Prinivil, Univasc, Vasotec, Zestril.117
3. currently take a calcium channel blocker
-common names include: Adalat, Calat, Cardene, Cardizem,
Covera, Dilacor, Dynacirc, Isoptin, Nimotop, Norvasc, Plendil,
Procardia, Sular, Tiazac, Vascor, Verelan.
4. currently take a beta blocker
-common names include: Atenolol, Betapace, Blocadren,
Brevibloc, Cartrol, Inderal, Kerlone, Levatol, Lopressor,
Sectral, Tenormin, Toprol, Visken, Zebeta.
5. currently take another type or a combination of medications for
lowering blood pressure, if so please list name of medication(s):
6. do not currently take any blood pressure-lowering medications.
66.Do you currently take any medication to alter your blood cholesterol levels
(called "hypolipidemic" medications)?
1. currently take a cholesterol synthesis inhibitor
-common names include: Lescol, Lipitor, Mevacor,
Pravachol, Zocor.
2. currently take niacin
3. currently take a fibrate
-common names include: Atromid, Lopid.
4. currently take a bile acid-binding resin
-common names include: Colestid, Questran.
5. currently take another type or a combination of medications for
altering blood cholesterol levels, if so please list name of
medication(s):
6. do not currently take any blood cholesterol-altering
medications.
67.Do you currently take any medication to lower your blood sugar levels (called
"hypoglycemic" medications)?
1. currently take a class I hypoglycemic
-common name: Glucophage.
2. currently take a class II hypoglycemic
-common name: Precose.
3. currently take a class III hypoglycemic
-common name: Amaryl, Diabeta, Diabinese, Glucotrol,
Glynase, Micronase.
5. currently take another type or a combination of medications for
lowering blood sugar, if so please list name of medication(s):
6. do not currently take any blood sugar-lowering medications.118
68.Do you currently take any medication to improve your mood (called
"antidepressant" medications)?
1. currently take an SSRI antidepressant
-common names include: Paxil, Prozac, Zolofi.
2. currently take a tricyclic or other antidepressant
-common names include: Adapin, Asendin, Elavil, Etrafon,
Limbitrol, Norpramin, Pamelor, Sine quan, Tofranil, Triavil,
Vivactil.
3. currently take another type or a combination of medications for
reducing depression, if so please list name of medication(s):
4. do not currently take any antidepressant medications.
69.Do you currently take any antioxidant medications or supplements?
1. currently take probucol
2. currently take Vitamin E supplements
3. currently take Vitamin C supplements
4. currently take another type or a combination of antioxidants, if
so please list name of medication(s) or supplement(s):
5. do not currently take any antioxidants.
70.Have you ever received a positive angiographic, ECG (electro-cardiogram), or
thallium test?
1. yes
2. no
3. don't know
If your answer to question 70 is "no". please skip questions 7 1-72.
71.On what date did you first receive a positive angiographic, ECG, or thallium
test?
Month (i.e., "January" is "01")
Day
Year
72.On what date did you experience your most recent positive angiographic, ECG,
or thallium test?
Month (i.e., "January" is "01")
Day
Year